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Mining Breast Cancer Genetic Data for Improved Diagnosis 
 
Rouba Samir Zantout 
 
Abstract 
Breast cancer is an ominous disease that affects many women; it is ranked as the fifth 
cause of death and the second common cancer worldwide.  Analyzing breast cancer 
gene expression profiles for understanding genetic similarities is a very challenging 
problem, since a lot about the functions of many genes is still to be revealed. 
Computational techniques have proved reliable to support the clinics in diagnosis and 
therapy. In this thesis, we use a data mining method to find a logical correlation 
behind the clustering pattern of the genes involved in breast cancer. We design a 
growing hierarchical self-organizing map (GHSOM) to mine gene microarray data. 
GHSOM configures its topology during unsupervised learning process according to 
the features of the input genes microarray data, without other prior knowledge. 
GHSOM clusters genes that are related to each other by utilizing their microarray 
expression levels. We have applied GHSOM to 24,481 genes of DNA microarray of 
breast tumor samples from 117 patients. Our results have revealed 17 genes that are 
likely to be correlated, in small subsets, with four breast cancer marker genes. This 
result is promising for diagnosis and for better understanding of breast cancer. 
 
Keywords: Bioinformatics, Growing hierarchical self-organizing map, Data mining, 
Breast cancer, Gene expression data analysis, Microarray, Clustering, Self-
organizing map. 
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1CHAPTER ONE 
I-INTRODUCTION
Cancer leads to around twenty five percent of death [1]. Breast cancer is the second 
common cancer and the fifth cause of death worldwide [2]. It is also known to be the 
most common malignant tumors among woman in the age of group 33-55 years [3]. 
It is intuitive that the early diagnosis of breast cancer would increase the survival rate 
[3]. 
There are a number of methods to identify and monitor breast cancer; among these 
are: (a) mammograms, and (b) luminescence techniques that are applied for breast 
cancer diagnostics, lymph node status, histological grade determination and genes 
microarray data analysis. One of the most potentially-specific breast cancer 
prognosis tools is the analysis of genetic data. Wet-lab methods for analyzing genetic 
data are complex, very time-consuming, and costly, especially that we normally need 
to explore and analyze a large number of genes. Hence, computational methods are 
required for analyzing enormous amounts of genetic data in order to reduce time and 
cost. Distinct molecular subtypes of breast tumors can be described according to the 
gene’s expression profile [2]. In this methodology data are usually collected on 
thousands of genes for a patient. Thus, the sample data contains a massive amount of 
genes of which we have to select the most informative ones. Gene expression 
profiling has the potential to yield outstanding results and to outperform all currently 
used clinical indicators for disease predictions and monitoring [4]. Therefore, 
identifying correlated genes that are involved in specific subtypes of breast cancer 
can offer a remarkable contribution to the diagnosis of this disease. 
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profiling has the potential to yield outstanding results and to outperform all currently 
used clinical indicators for disease predictions and monitoring [4]. Therefore, 
identifying correlated genes that are involved in specific subtypes of breast cancer 
can offer a remarkable contribution to the diagnosis of this disease. 
 
Several researchers have reported computational methods for mining gene 
microarray data. Opera [5] used a Self Organizing Map (SOM) to identify tumor size 
by clustering the mammograms images. Lopez [2] studied the association between 
prognostic factors and whole genome expression data in breast cancer.  They used 
“Fuzzy” association rule mining algorithm to obtain number of interesting 
associations and evaluate them. Gruzdz [6] utilized the Self Organizing Map to find 
similarities and dissimilarities based on genes expression characteristics. Gene 
expression can predict which useful therapy methods are most suitable for breast 
cancer patients. Veer [4] used DNA microarray analysis on breast tumors and they 
applied unsupervised hierarchical clustering then supervised classification to identify 
genes of indicative signature in patients of poor prognosis at diagnosis of negative 
lymph node, and with patients with BRCA1 carriers. Sorlie [7] refined subtypes of 
breast tumors by distinguishing patterns of gene expression. They used hierarchical 
clustering and dendrograms to subdivide total of 115 samples of malignant breast 
tumors. Covell [8] used unsupervised Self Organizing Map to classify tissue samples. 
They used SOM to separate the tumor expression datasets from the normal ones. 
Ribar [3] applied classification of breast cancer luminescence data using Self 
Organizing Maps. Domany [9] introduced a new technique “Coupled Two Way 
Clustering (CTWC)” to mine gene microarray data. The technique is summarized in 
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identifying sets of genes (clusters) out of the expression dataset; these clusters 
partition the samples into biological classes. 
 
In this thesis, we design a Growing Hierarchical Self Organizing Map (GHSOM), 
which is a clustering method, in order to find logical correlation among genes that 
are involved in breast cancer. The GHSOM mines the gene Microarray data 
developed for a number of breast cancer patients. GHSOM dynamically configures 
its topological structure during unsupervised learning according to the input breast 
cancer microarray data, where no previous knowledge is available on the involved 
genes. 
 
We use a DNA microarray dataset from 117 patients with breast cancer. The data 
involve 24,481 genes. We divide the dataset into four groups. For example, one 
group of patients is less than 55 years in age and who continue to be disease-free 5 
years after receiving their therapy. We aim to identify genes that are correlated with a 
set of breast cancer marker genes (ESR1, IL1R1, BRCA1 and BRCA2). We report 
promising results that may help the biologists and the oncologists in detecting breast 
cancer and in improving treatment methodologies. 
 
This thesis is organized as follows. In Chapter 2, we explain our research’s objective 
and describe our problem. In Chapter 3, we preset previous works that are similar to 
our interest, such as researches applied the Growing Hierarchical Self Organizing 
Maps in different disciplines, researches applied mining techniques for cancer and 
breast tumors and other researches explained how to evaluate the cluster’s outcomes 
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quantitatively and qualitatively. In Chapter 4, we give an overview of unsupervised 
methods, in particular Self Organizing Maps (SOM) and Growing Hierarchical Self 
Organizing Maps (GHSOM), and we present the GHSOM technique designed for 
breast cancer microarray data. In Chapter 5, we describe our experimental work, 
discuss and validate the results. In Chapter 6, we present the summary of findings 
and suggest further works. 
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CHAPTER TWO 
II-RESEARCH OBJECTIVE 
2.1 Background 
Alteration in gene expression often leads to alteration in cell’s behavior and is often 
pathological. This makes the detection and monitoring of gene expression alterations 
in different conditions worth studying. An expression profile usually refers to the set 
of genes that are transcribed (expressed) from genomic DNA. The transcription of 
DNA yields mRNA, the latest gets translated into a protein that plays a certain 
function in a cell. If this protein is important for the regulation of cell division, the 
over expression of this protein might lead to the deregulation of cell division, hence 
to pathology, similar to the one found in cancers. Hence it is intuitive that, 
understanding genetic expression profiles is of great help to understand cancer 
pathology and the function exerted by individual genes correlated with the 
pathology. 
It is interesting to have an overview of the technology behind these genes expression 
profiles. In short, the mRNAs are extracted from cells of different samples to be 
compared, next scientists make fluorescently labeled cDNA out of these RNA 
samples (different color fluorescence) and then hybridize the cDNA from the 
different samples to the array, where each spot, on the array, is a measure that is 
matched to expression level for a specific gene (figure 2.1). The importance of DNA 
hybridization is in producing a huge number of expressed genes that can be analyzed 
at the same time under the same conditions; and this technology is progressive very 
quickly in the past few years. 
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Figure 2.1: bonded sample on a glass, genes labeled in a position - refer to perou [7] 
Different fluorescent intensities reflect different expression levels of the genes as 
shown in figure 2.2. 
 
Figure 2.2: cDNA chip resulted from fluorescent 
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There is a special designed scanning microscope, and many developed software such 
as GeneChip, which analyzes generated expression levels into meaningful biological 
results. Figure 2.3 shows a summary of the process that we discuss in this section.  
 
Figure 2.3: Summary of gene microarray process from samples into biological and computational 
analysis 
Figure 2.3 shows how the hybridized DNA (spots) is scanned to produce set of 
meaningful and numerical expression level per each gene in a sample; a result is 
shown in figure 2.4. We will use such samples in this research to monitor and track a 
genes of interest related to breast cancer tissues.  
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Figure 2.4: Sample of genes and their expression level values 
We select expression levels of breast cancer samples. Breast cancer is well described 
by gene expression profiles [2]. There are many types of breast cancer; the disease 
varies from invasive breast cancer (IBC) that breaks out from the breast duct and 
affects the normal breast tissues; to the lobular cancer that tends to spread to both 
breasts. Most patients with this kind can survive after five years of treatments. 
Sometimes, invasive breast cancer cells access the lymphatic vessels hence the 
presence of cancer cells in lymph nodes indicates the initial metastasis of the disease. 
When the cancer cells spread out of the lymph nodes and access the blood vessels, 
the breast cancer will then easily spread out all over the body. This kind of breast 
cancer metastasis is indicative of poor prognosis.   
Analyzing breast tissues, specifically genes expression levels, is a very indicative 
way to test cancer existence or its progression (metastasis stage). In addition, this 
kind of analysis is very important to measure the effectiveness of breast cancer 
treatments, and maybe to deduced new subtypes of breast cancer that are still 
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undefined and even to provide information on the function of genes/proteins that is 
not known yet [9]. 
However, it is reported that using clustering, as a data mining method, is one of the 
most effective tools to analyze gene’s expressions data of tumor tissues [10]. Hence 
in this research, we adopt unsupervised clustering to address a set of questions 
related to alternation of gene expression levels in breast cancer samples.  
 
2.2 Problem Description 
Our study focuses on identifying genes that are involved in breast cancer tumor 
tissues; specifically we are looking for genes that are correlated to the four marker 
genes (ESR1, IL1R1, BRCA1, BRCA2) and that are involved in breast cancer 
metastasis. 
 In order to narrow down the solution objective, our analysis focus on breast cancer 
microarrays data from 117 different tissues, aiming to cluster 24,481 genes into 
groups that have correlated pattern of expression, which can provide insights into 
gene-gene interaction and gene function. Particularly, to identify genes that tend to 
be clustered with other genes that have been recognized with molecular markers; for 
instance, estrogen receptor (ER) grade is used to classify tumors based on its 
molecular behavior [6]. Significant changes in ESR1 expression levels are recorded 
(the ER-alpha itself), these expression levels encode the estrogen receptor (ER). 
Excess in estrogen may impact breast cancer risk, since this excess stimulates breast 
cell growth. ER status may have noticeable influence on survival from breast tumors 
[6]. In fact, ESR1 was found to be amplified in 20.6% of breast cancers; survival for 
women with the ESR1 amplification was surprisingly longer [11]. In order to 
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understand breast cancer development, it is worth to study the relationship between 
ESR1 and other genes; since ESR1 impacts the mechanisms of breast cancer 
progression and its subtypes. Identifying a group of genes with mutations (or 
amplifications) correlating with ESR1, would reveal important information about the 
function of those genes, as well as, information about the development of ESR1 
related breast cancers. 
  
IL1R1 gene is identified among a few other genes as a result of clustering breast 
cancer data; where IL1R1 (interleukin 1 receptor-like 1) gene is part of a regulating 
mechanism of protumorigenic activities, hence IL1R1 may be associated with breast 
cancer [8]. We consider IL1R1 as a gene to be traced throughout the clustering 
process and we mark the genes that mostly tend to be clustered with IL1R1. 
Thus this research has the following main objective: to identify genes that are 
correlated with ESR1 and IL1R1. In addition, this study will correlate BRCA1 and 
BRCA2 genes, which are known markers for early onset and late onset breast 
cancers, with ESR1 and with other genes. BRCA1 and BRCA2 genes ensure stability 
of the DNA and help in controlling cell growth. In fact, women are about five times 
more likely to develop breast cancer if they inherited a harmful mutation in BRCA1 
or BRCA2. 
It is intuitive that finding a set of clusters that are near optimal from enormous 
microarray genes data is hard problem (NP). 
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2.3 Genes of Interest  
Our objective is to discover a set of genes that is positively or negatively correlated 
with the marking genes ESR1, BRCA1, BRCA2 and IL1R1. We will name this set as 
the target genes. The set of target genes is divided into two categories: 
1. Group A (11 genes): set of genes that is derived from previous 
publications as positively or negatively correlated with ESR1, BRCA1, 
BRCA2 and IL1R1 as a result of SOM technique (Covell [8]; Gruzdz 
[6]). These genes are: CDH3, LIV-1, VAV3, LAD1, GATA3, GSTP1, 
SLPI, FABP7, RAB5EP, GALNT3, NAT1. Description of these genes 
and their known functions are described in Appendix I. 
2. Group B (72 genes): set of genes that are advised by a Biologist, where 
all these genes would be potentially related to breast cancer. These genes 
play a role in cancer cell metastasis and we might expect them to be in the 
same cluster with marker genes, since they are all modulate actin 
dynamics leading to cancer cell metastasis; it would be quite interesting 
and not unexpected if they are clustered with ESR1, BRCA1, BRCA2 and 
IL1R1. These genes are:  
RAC1, PIK3R2, ARHGEF16, VASP, ARHGDIB, DIA1, EGFL3, EGR1, 
T-STAR, DJ-1, ARHGDIB, RAC3, RHO6, RHO7, RHO, CDC42, 
ROCK2, LIMK1, AKT1, AKT2, AKT3, PTENP1, PIK3C2B, PIK3C2A, 
PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3C3, PIK3R3, GEF, 
ARHGEF1, ARHGEF2, ARHGEF4, ARHGEF5, ARHGEF6, 
ARHGEF9, STAR, TRIO, EGR4, EGFR, EGFL6, EGFL5, EGF, PLCD4, 
PLCD1, PLCG2, PLCG1, PLCB4, DIAPH3, DIAPH2, DIAPH1, 
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WASPIP, WASL, IQGAP2, ARHGAP8, ARHGAP6, ARHGAP1, 
VAV2, VAV1, SMURF1, VEGFB, VEGF, TIAM2, PAK6, PAK3, 
PAK2, PAK1, CDC42BPB, ARHGEF12, ARHGEF11, ARHGEF10. 
Description of these genes and their known functions are described in 
Appendix I. 
 
2.4 Research Questions and Objective 
The objective of this work is to apply unsupervised clustering based on the GHSOM 
using microarray gene data for breast cancer tissues. The research questions are: 
o What are the genes that tend to be clustered with ESR1 in breast cancer 
microarray, as a result of applying GHSOM as unsupervised clustering?  
o What are the genes that tend to be clustered with IL1R1 in breast cancer 
microarray, as a result of applying GHSOM as unsupervised clustering? 
o What are the genes that tend to be clustered with BRCA1 in breast cancer 
microarray, as a result of applying GHSOM as unsupervised clustering? 
o What are the genes that tend to be clustered with BRCA2 in breast cancer 
microarray, as a result of applying GHSOM as unsupervised clustering? 
 
In order to address these questions; we track the four marker genes ESR1, BRCA1, 
BRCA2 and IL1R1 in the resulting clusters, and deduce observations based on the 
behaviors of those genes while clustering. We apply GHSOM using different 
parameters on various breast cancer microarray datasets. We select the input 
parameters of GHSOM that yield the least cluster’s quantization error of our marker 
genes (ESR1, IL1R1, BRCA1, and BRCA2). In addition, we compare the resulting 
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GHSOM clusters with quantum clustering ones that are rectified using Bayesian 
Information Criterion (BIC).  Then, we evaluate the results by comparing the mean 
quantization error of each cluster of GHSOM with SOM applied on same datasets. 
We deduce a set of genes that tend to appear with (ESR1, IL1R1, BRCA1, and 
BRCA2) no matter how we change the selection of neighborhood genes’ sets, and 
regardless of the location of the initial genes’ set. Also, we compare the resulting 
genes with previous publications, and we try to correlate these genes to breast cancer 
and metastasis based on their bio-genetic behaviors. 
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CHAPTER THREE 
III- PREVIOUS WORK 
3.1 Growing Hierarchical Self Organizing Map 
Mansour [12] used Growing Hierarchical Self Organizing Map (GHSOM) to address 
Intrusion Detection in Network Systems, This monitors network activities and 
produces alarms when it detects non-trustful actions in the network; such kind of 
alarms is called a true alarm. False alarms are produced when the NIDS identified 
trusted actions as attack.  They utilized GSHOM, which adjusts its structure 
according to the features of the input network data. They clustered the network data 
using GHSOM algorithm into two types of alarms. Thus they provided a valid tool to 
support network administrator in making decisions of which alarms are false and 
which are true. They selected 0.3 and 0.01 as breadth and depth parameters 
respectively to control the GHSOM topological structure. 
 
Saavedra [13] presented K-Dynamic Self Organizing Maps (KDSOM). This has the 
ability to grow by learning the topology of input data. They tested the algorithm on 
Winsconsin breast cancer datasets and wine datasets. The breast cancer data contains 
569 records with 30 samples; this database is a mixture between tumor and normal 
tissues. The result of their work is compared with Growing Self Organizing map, in 
terms of the number of units (neurons), the number of maps (grids), and performance 
of training and testing datasets; the growing parameter was set to 0.05.   
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Moreno [14] presented a Robust Growing Hierarchical Self Organizing Maps 
(RGHSOM). GHSOM is known to be sensitive to noise and outliers which adjusts its 
topology. RGHSOM overcomes this shortcoming by being resistant to these 
deviations. They tested this algorithm for the Winsconsin breast cancer datasets and 
the phoneme datasets of recognition problem. They partitioned the breast cancer data 
into testing (269) and training dataset (300). The result of their work is compared 
with growing hierarchical self organizing map, in terms of the number of units 
(neurons), the number of maps (grids), and performance of training and testing 
datasets; the performance of RGHSOM shows better results than GHSOM for both 
input datasets. 
 
Dittenbach [18] used Growing Hierarchical Self Organizing Map to organize textual 
information according to their similarities. GHSOM develops its hierarchical 
structure according to characteristics of the textual input data during unsupervised 
training process. They categorized newsletters into politics, sports, social, and others 
according to relevance of textual input to these types. Many other publications aimed 
to solve real life problem using clustering of GHSOM; for example, Alahakoon [19] 
used Dynamic Self Organizing Map with supervised expansion to discover 
knowledge from a large amount of textual information. 
 
3.2 Microarray Data Mining Methods 
Data mining contributes to analyze data with no prior information. Many mining 
algorithms are recommended to analyze genes microarray data. Hayward [20] 
applied machine learning techniques to detect clinical performance of pancreatic 
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cancer database. They compared the performance of linear and logistic regression 
methods. They used clinical database for 91 patients’ treatments for pancreatic tumor 
from University of Massachusetts Memorial Hospital. Classification targets include 
survival months of patients, surgical results, and tumor types. They applied Weka 
machine learning workbench to generate predictive model based on clinical 
diagnosis for binned and nominal targets. Then they evaluated metrics of predictive 
performance with random re-seeding. They showed that predictive performance 
using machine learning tools is better or similar to the results produced from 
regression and linear methods. 
 
One famous data mining technique is the clustering. Clustering is effective algorithm 
used for gene expression applications. Researchers usually have to analyze enormous 
expression levels of genes for different patients’ profiles and biological conditions, at 
the same time. Clustering helps in analyzing this massive data by grouping genes that 
share similar expression profiles. The target of microarray clustering is to find genes 
that share regulatory mechanisms. 
Shah [1] analyzed gene expression datasets of ovarian, prostate, and lung cancer 
tissues. They proposed gene-search algorithm, this algorithm analyzes data of genes’ 
expressions. Gene-search algorithm used a genetic algorithm and heuristic (CFS) for 
data pre-processing, and decision tree for data prediction. They mixed normal data 
with tumor ones, and produce a training datasets per cancerous type. They applied 
integrated gene-search algorithm on these datasets, and evaluate the results by 
measuring the accuracy of training and testing data, and the size of genes sets. The 
accuracy of their algorithm varied from 94-98%. They deduced a technique to early 
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detection of prostate and ovarian tumors, and they classified lung cancer using the 
search-gene method. Their research helps in tumor detection, treatment selection and 
drug development. 
 
Yobon [21] applied microarray gene selection using Self Organizing Map (SOM) on 
carcinoma, leukemia and lung cancer. They proposed a new technique helps for 
cancer prediction from DNA microarray data. The prediction starts by selecting 
genes by using statistical methodology (Gene Selection), clustering cancerous data 
by using Self Organizing Map for microarray gene (MGS_SOM), then generate rule 
creation process (Rule Creation) and validation process (Rule Evaluation). Their 
experimental result shows the roles of genes with 100% accuracy for cancer 
prediction; for instance, if gene number T64297 is less than 703.76, then the person 
is classified as carcinoma patient. 
 
Domany [9] created coupled two ways clustering (CTWC) and applied it to gene 
microarray data. The algorithm is based on iterative clustering on colon and 
leukemia. The algorithm identifies relevant subsets of microarray data, and then 
discovers partitioning correlation to the remaining. For instance, they applied CTWC 
on known ALL/AML samples to determine which cluster of genes can distinguish 
between the two classes, and they found a single stable cluster of 60 genes that 
indicates separation of the samples into AML and ALL. 
 
 
 
18 
 
3.3 Computational Methods Related to Breast Cancer  
One of the famous clustering techniques is the Self Organizing Map. Opera [5] used 
Self Organizing Map (SOM) clustering to detect and characterize cancer tumors in 
mammograms. They try to address a complex problem of detecting possible cancer 
area, since cancerous cells are known to be widely scattered and because there is a 
thin line separates cancerous from healthy zoon. They used SOM to separate the 
cancer suspicious regions; they considered SOM as useful tool for tumors discovery. 
 
Markey [22] used SOM to cluster heterogeneous breast cancer dataset (2258 cases), 
the database is based on mammographic findings and patients age. The resulted 
clusters showed rational separation of clinical diagnosis such as masses, calcification 
and distortion. 
 
Lopez [1] studied the association between prognostic factors and genome expression 
data in breast cancer.  They used Fuzzy association rule mining algorithm to obtain 
number of associations and evaluate them, they related GREB1 and PDZK1 genes to 
ER index and phenotype. These two genes are known to regulate estrogen that is 
expressed in hormone responsive to breast cancer. Another association rule they 
deduced, is the involving of PTHLH gene in cancer metastasis. 
 
Gruzdz [6] utilized the Self Organizing Map to find similarities and dissimilarities of 
genes based on their expression characteristics. They aimed to find the set of genes 
that are related to estrogen receptor 1 (ESR1). ER status is involved in serious impact 
on breast tumor survival, since its expression alternations appear in many tumor 
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subtypes and it is noticed that ESR1 is correlated with other marker genes. Gruzdz 
relied on studying the distance between genes attributes in order to cluster these 
genes. Genes that belong to same cluster may share same functional groups; 
therefore, studying the behavior of a cluster whose genes shared same correlated 
expression characteristic is more suitable than studying a gene. Gruzdz applied Self 
Organizing Map using different distance functions to measure genes similarities. 
They applied SOM on total of 115 malignant breast tumors and 7 benign tissues; 
they tested Spearman correlations as well as the Ranked Entropy. Their analysis 
targets the groups of genes that are mostly related to breast cancer; they found a 
group of genes correlated with ESR1; i.e. they are placed repeatedly in ESR1 cluster 
or in its neighborhood. In spite of that SOM outcomes depend on random values of 
initial grid, they found significant genes that are always close to ESR1. Some of 
these genes are already identified in previous researches [6]. They found a group of 
genes close to ESR1 (positively correlated), and they are: GATA3, VAV3 that are 
down regulated during tumor development; LIV-1 is a breast cancer associated 
protein related to cancer development, it is major role relied in transport zinc 
enzyme; NAT1 is known of its impact on breast cancer risks while transcription 
process, it is affected by the environmental factors. Moreover they found the gene 
RAB5EP which is noticed to have major role in cancer progression. Gruzdz stated 
that, negatively or positively correlated genes with ESR1 shall be treated with same 
importance. Therefore, the genes that are negatively correlated with ESR1 according 
to Gruzdz are: CDH3 plays major role in cell adhesion and loss of heterozygosity in 
both prostate and breast cancers; GALNT3 is marked as tumor differentiator; GSTP1 
is usually up regulated in human tumors since it is responsible on detoxification, 
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therefore its expression increases as tumor progresses, and it results in resistance to 
treatment. However, Gruzdz declared that this type of study needs more extensive 
researches and active cooperation from biologist and oncologist. Their research 
confirms the importance of ESR1 and its related genes mechanisms in underlying 
many breast cancer subtypes. 
Gene expression levels can predict clinical results of breast tumors, Veer [4]. They 
used microarray analysis on 117 breast tumors of patients in the age of group 33-55 
years; the same data we used in this thesis. They applied unsupervised hierarchical 
clustering then supervised classification to find genes of poor prognosis at diagnosis 
of negative lymph node, and with patients with BRCA1 carriers. Veer declared that 
expression profiles of genes will offer outstanding outcomes better than all clinical 
indicators in diagnosis. In this paper, Veer presented how to select breast cancer 
patients who would positively responses to adjuvant therapy. They deduced a criteria 
out of gene expression profile that can be an indicator of how successful is the 
adjuvant therapy; specifically the signature of ER can be used to determine how 
efficient this treatment will be; the signature that trigger BRCA1 status may develop 
the diagnosis of breast cancer of hereditary type; genes that are up regulated in 
tumors, with a negative breast cancer diagnosis, are potential markers for developing 
drugs of malignancy diseases. 
 
Sorlie [7] refined subtypes of breast tumors by distinguish patterns of gene 
expression. They used hierarchical clustering and dendrograms is used to subdivide 
total of 115 samples of malignant breast tumors subgroups: ERBB2 over expressing, 
basal-like, luminal-like, and normal breast tissue-like. They included information to 
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development on distance metastasis, and associate subtypes with clinical features. In 
spite of that, studying gene expression profiles showed its ability to separate tumors 
based on molecular and clinical parameters - such as metastasis time of development, 
ER status - the observation of BRCA1 mutation is strongly associated with a basal-
like type of tumors leading to poor prognosis. 
 
Covell [8] used unsupervised Self Organizing Map to classify tissues samples. Their 
research relied on the concept that gene expression signature is common among more 
than one cancer subtypes. Thus, they used SOM to spate the tumor from normal 
expression datasets. They used 280 samples of which 190 are tumors samples 
assigned to 14 tumor type. They started by applying filter on microarray data to 
eliminate genes that have minimum alternation in each tissue dataset; i.e. genes with 
expression levels less than 0.5 deviation from the mean. The filter yields set of 5,183 
genes that are further normalized. The filtered data 280 X 5,183 were clustered using 
SOM to produce 38 X 23 maps. Visualizing the results with two dimensional 
projections (dendrograms), they found that SOM has completely divide genes 
expression related to tumors from those of normal ones; each cancer types have been 
colored differently. After they used SOM to separate tumor from normal samples, 
they used Fuzzy classification to assign probabilities for all tumor classes to each 
SOM node. They found near perfect classification for Leukemia, central nervous 
system; some poor classification for lung, ovarian and breast cancers. Since the 
selection of significant genes which classify tumors is based on genes expressions 
alternations, it is quite important to identify these genes as potential marker for 
cancer subtype, Covell [8]. As a result, classifying tumor and normal tissues 
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identifies a set of genes that are over expressed in normal tissue and down expressed 
in tumor tissues. Hence, few genes have been selected for breast cancer group; only 
IL1R1 (interleukin 1 receptor 1) gene is marked among this few genes. It is thought 
that IL1R1 is part of the regulation machinery contributed in breast tumors 
protumorigenic activates. 
 
Ribar [3] applied classification of breast cancer luminescence data using Self 
Organizing Maps. The data includes normal and tumor tissue, it is collected from 200 
nm/min scan rate and excitation wavelengths from 330 to 550 nm with 0.5 nm 
increments, averaging 4 scans to obtain the spectra. They were able to classify this 
type of breast cancer data into two groups (normal and tumor) tissues. 
 
Domany [9] introduced a new technique “Coupled Two Way Clustering (CTWC)” to 
mine gene microarray data. The technique is summarized in identifying sets of genes 
(clusters) out of the expression dataset; these clusters partition the samples into 
biological classes. They tested CTWC on breast and colon cancer datasets from 
Stanford. One of breast cancer dataset is composed of 84 samples of 65 tumors, and 
19 cell lines; dataset represents 8,102 genes. They produced the same result of Perou 
[7] without filtering the data; and they found more tumor classifications, these 
classifications are produced as a result of the identified cluster of separation genes 
using CTWC. These classifications have no clear biological interpretation at that 
moment. 
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3.4 Cluster Evaluation  
Many publication used GHSOM as a clustering technique in real life applications; 
however, validating the clusters and its integrity varied from one research to another. 
Batista [25] who applied GHSOM for handwritten digit recognition; they compared 
GHSOM algorithm performance with SOM, and found that it is 100 times faster.  
They trained SOM to reach equivalent size to GHSOM; they stopped GHSOM 
training process when it reached a quantization error equivalent to that of SOM. 
 
Varshavsky [23] utilized K-Mean algorithm as spherical distribution and Quantum 
clustering that does not consider spherical clustering. They used these two algorithms 
to analysis genes expression and to categorize protein sequences. The optimal 
parameter setting for these two algorithms is selected according to Bayesian 
Information Criteria (BIC). They used Colon dataset of 62 gene expression samples 
mixed between 40 cancerous tissues and 22 healthy ones; and other test for Yeast 
dataset. They applied different parameters, several iterations on the two clustering 
algorithms, then they compared the results with each other by applying BIC criterion. 
The maximum score given by BIC yields the optimal values for the clustering 
parameters. 
 
Other researches evaluates clustering quantitatively by comparing the number of 
clusters between two different clustering algorithms, the absolute positions and 
relative positions of the clusters, the size of the cluster, the shape and density of the 
clusters. However, the quantitative evaluation depends on the research’s objective. 
Gupta [24] applied parameter selection based on Bayesian Information Criterion 
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(BIC) and Akaika Information Criterion (AIC), then they extended the research to 
use a cluster splitting approach based on Principle Direction Division Partitioning 
which improved the efficiency and the accuracy of the clusters. They compared the 
Root Mean Square Error to compare the clusters after and before splitting. 
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CHAPTER FOUR 
IV-GHSOM ALGORITHM 
 
4.1 Background 
This chapter provides an overview about data mining techniques of unsupervised 
learning algorithms. One of the known techniques is the Growing Hierarchical Self 
Organizing Map (GHSOM). It improves the limitations that are presented in other 
methods such as Self Organizing Map (SOM). Furthermore, in this chapter we 
present and discuss GHSOM parameters and how we leverage GHSOM for better 
results. 
 
4.2 Unsupervised Learning 
Mining data to explore its content and deduce informative knowledge is one of the 
hot topics of today.  Pattern recognition or data mining depends on representation of 
high dimension data. One of the most suitable approaches is how to group this high 
dimensional data into meaningful categories based on data similarity; i.e. into 
optimal clusters. These clusters will be helpful for further analysis and study. For 
instance, a textual data that contains same purpose or relates to same topic can be 
categorized into sections based on its textual relevance. Object in a cluster 
corresponds to a vector in a multi-dimensional space. Objects usually cluster together 
based on their similarity with respect to the other objects in the pattern [12]. 
Unsupervised learning helps to group objects into clusters based on object’s semantic 
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similarities. Thus, clustering will help in detecting useful information and 
relationship among these objects. Usually, the problems we try to address in such 
techniques have no prior information on the data, which make the clustering 
technique a very helpful tool to interpret this data and analyze it. 
SOM, is an abbreviation to Self Organizing Map, is one of the techniques of 
unsupervised learning algorithm. It is originated by Kohonen in 1995 [12]. It maps 
high dimensional data onto a smaller, separated network structure. However, SOM 
has some known limitations; the total number of expected clusters needs to be 
predicted before SOM starts interpreting the data; i.e. the total number of maps and 
units shall be determined beforehand. In addition, SOM does not provide hierarchal 
relations between input data. Accordingly, it is worth considering algorithm which 
predict the total number of clusters and its units throughout data exploration; i.e. 
unsupervised learning approach to produce clusters and to consider hierarchical 
structure among these clusters. Thus, GHSOM, is an abbreviation to Growing 
Hierarchical Self Organizing Map, was introduced to address the limitations of SOM 
[15]. 
 
4.3 Clustering 
Clustering targets to partition the input data into set of groups; where the objects in 
each group are much related or similar to each another than the objects in other 
groups.  
Let O={ o1,…,ok } be a set of objects, and let G={ g1,…,gk} be a set of groups that 
are resulted from dividing O into disjoints sets. Each group Gi  is called a cluster. 
Two objects match in G if they belong to the same cluster in G. Object corresponds 
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to data vector, and degree of similarity between two objects is calculated with respect 
to the vectors corresponding to these objects. 
Clustering algorithm is unsupervised learning techniques; it targets to find a set of 
clusters that are near optimal of a given dataset. The decision of how to find division 
that will be optimal is hard problem (NP). The difficulty is summarized in how to 
find an object that is more closely similar to a cluster’s elements than the other 
objects in the dataset. In other words, the objective of clustering is to partition set of 
objects, corresponding to set of vectors, into consistent and well-divided clusters 
[12]. There are no best criteria available that guarantee optimal clusters; especially 
that the clustering is always subject to user’s requirements and to the nature of the 
problems. Traditional trial and error to find optimal clusters is proven to be NP-hard. 
In addition, clustering deals with no prior information that is available on the data; 
i.e. it targets to find structure in a collection of unknown data; and hence unique 
clusters based on observation provided throughout the learning process. 
 
4.4 Self-Organizing Maps 
 Self Organizing Map which is known as SOM, is proposed by Teuvo Kohonen in 
1995. It is a technique similar to neural networks in human brain, it is unsupervised 
learning method. It projects high dimensional data onto (two-three) dimensions. It 
tired to preserve the maximum input space topology. SOM partitions data into set of 
two-dimensional geometric pattern (lattice). The number of cluster in the pattern, is 
chosen based on the expected number of resulted groups, which assumes some prior 
information on the input data [12]. The distance between two objects in the space 
gives the level of similarities of these objects. Distance can be interpreted by many 
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functions such as Gaussian, Spearman, etc. This similarity level is directly involved 
in identifying the partitioned clusters. The target of SOM is to find best matching 
between high dimensional input data and to result two-dimensional space of objects, 
without distorting the topological architecture of the input data, thus SOM is used as 
a clustering tool [12]. Clustering using SOM does not need to pre-assumed the shape 
of the clusters, in contrast to other clustering algorithm; for instance, K-means, is 
best suitable for circular clusters. The SOM learns during training process, during 
this phase each object is selected randomly in the input space and presented in the 
map, then to find its similar objects. 
There is an n-dimensional weight vectors, each vector corresponds to a unit in the 
input space. During the iterations in the algorithm, the distance function is calculated 
between randomly selected input vector v; distance is calculated based on the weight 
assigned to each vector wi. The unit that has shortest distance to selected input vector 
shall be considered the winner u for v. the distance function is calculated as follows: 
 
||v(t) – wu(t)||   ||v(t) - wi(t)|| for i=1,2,…,n  i.e.  u = mini{||v(t)- wi(t)||}  (1) 
 
where t represents the time in iterations; wi represents the weight vector of the ith 
object. Hence the output is linked to the position of best object with shortest distance.   
From geometric point of view, the weight vector of each best unit corresponds to the 
center of a cluster. The updated units vary throughout the iterations, and updated 
units are moving towards the input vector in steps, refer to figure 4.1. Thus the 
distance between updated units and the input vector shall be reduced. Weight of each 
unit is calculated as: 
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wi(t+1) = wi(t) + (t) [(v(t)-wi(t)] Lu(v),i for i=u and its neighbors  (2) 
 
Where Lu(v),I and (t) are the neighborhood function and the learning rate function 
respectively. 
The distance value converges towards zero with increase of time (t). 
Equations (1) and (2) describe how the training process works. 
One of the limitations of SOM is that one needs to identify the map size and the unit 
arrangement; therefore, for applications such as microarray analysis, the user does 
not know the microarray data structure and the network architecture. Thus 
determining the stopping criteria of when the data is trained enough, and when the 
maps are well organized will not be practical.  
Another limitation of SOM is that projection of unit does not represent hierarchical 
relationship among units. SOM is two dimensional maps (flat structure). 
 
Figure 4.1: units moving towards input vector 
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Hence the importance of adopting GHSOM is to overcome the limitation mention 
above in SOM algorithm; in another words GHSOM is a kind of neural network able 
to determine the number of unit arrangement (iterations), and the best network 
architecture (map size or number of clusters) during the unsupervised training 
process. In addition, GHSOM results a hierarchical relations among units to find 
appropriate structure and to reach the data mining goals. 
 
4.5 Growing Hierarchical Self-Organizing Maps 
The Growing Hierarchical Self Organizing Map (GHSOM) is the method proposed 
by Andreas Rauber (2002) to address SOM limitations (non-hierarchically 
architectures and fixed-sized).  
GHSOM results multiple layers as hierarchical structure, each layer is independent 
SOM. Each layer is initialized with four units. Each unit maybe extended down by 
adding new layer of another 4 units as a subsequent layer. In the same logic, each 
layer may grow in size to create new map. Hence GHSOM may result many layers, 
each layer may have one or more maps; each map contains many units (or clusters). 
Refer to figure 4.2 GHSOM structure 
 
Figure 4.2: GHSOM structure 
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The concept of GHSOM is to grow in horizontally and vertically; until the resulted 
structure is appropriate to the corresponding input data. 
GHSOM starts by 2x2 map at layer zero; it initializes its weight vectors randomly. 
Then, GHSOM trains this layer according to SOM algorithm. The expansion of the 
map is controlled in GHSOM by the quantization error of each object. 
The mean quantization error of an object i is calculated as follows 
 
mqei   =  (1/NU) ||wi-vj|| ,  for vj  Vi  NU = |Vi|, Vi  Ø    (3) 
where NU represents the number of projected vectors vj to object i; weight vector is 
wi of an object i, and  Vi  is set of input vectors.  
The mean quantization error mqe0  for layer zero is calculated as:  
 
mqe0   = (1/N)  ||m0-vi||,  for vi  D N = |D|     (4) 
D is the input dataset; N is the number of data vectors v in D, and m0 denotes the 
mean quantization error of input data. 
The mean quantization error (MQEmapi) of mapi  is defined as 
 
MQEmapi =   1/ Msmapi  mqei, for iMs Msmap=|Ms|   (5) 
Where Ms is the subset of the maps’ objects; the breath expansion is continued until 
MQEmap reaches a certain fraction T1 of the mqeu of object o, where o is the relevant 
parent object in the upper layer. Therefore, the vertical expansion of a map is stopped 
when  
 
MQEmap < T1 .mqeo         (6) 
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Where T1 controls the vertical expansion of maps; and it is within [0 to 1]. 
 
The stopping criterion of first map expansion is: 
MQE1 < T1 .mqezero          (7) 
mqe of all objects is calculated as in equation (3). More objects are added to layer 
zero if equation (7) is not satisfied. 
  
The object with the highest mqe is selected to be the error unit (err) according to 
err =  maxi( ||wi-vj||) ,  for vj  Vi No = |Ni|, Ni  Ø               (8) 
The weight vector is wi of an object i, and the set of projected vectors is vj into i; Ni 
is the sub-vectors vj.   
 
Calculating the distance dis to measure the degree of non similar is calculated as  
dis =  maxi(||wa – wb|| ),  wi  Ne           (9) 
wa represents the weight vector of the error object, Ne is the set of neighboring 
objects of o. 
 
Referring to figure 4.3, it shows the insertion of new object; the related neighboring 
objects are linked with arrows to their respective object. 
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Figure 4.3: unit insertion in GHSOM algorithm 
For the vertical expansion, the stopping criterion is:  
mqei < T2 . mqe0         (10) 
where T2 controls how deep the maps will be; and the value of T2 varied from [0 to 
1]. Objects having high mqe, needs to be clustered into deeper layer. This can be 
done by adding this object into new map in the lowest layer.  
Orientation of selecting the units is not random; weight vectors move, in a direction 
to their related parent’s neighbors in small steps.  
 
4.6 Growing Hierarchical Self-Organizing Maps for Microarray 
Data 
Overview of GHSOM algorithm is given in Figure 4.4 and this section describes how 
to design GHSOM for the microarray data contains genes expression levels of breast 
cancer. 
Input:  Set of data vectors {v1, v2, ….vN}  
Output: GHSOM: Growing Hierarchical maps 
Description: Set of layers, each layer contains set of maps, each map contains set of clusters; i.e. the 
(a) Column Insertion 
(a) Row Insertion 
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output is a set of hierarchical layers. 
Steps: 
Start with a 2x2 SOM at layer-0 
1- Set T1, T2, and ‘Orientation’ 
2- Initialize weight vectors of SOM (randomly for layer-0)  
3- Train SOM 
(a) [For layer-1 and below] Initialize the 2x2 n-dimensional weight vectors with the average 
of the weight vectors of their parent unit and its two direct neighbors; 
(b) Randomly select a data vector v(t) from the input data vectors [ For layer-one and below 
randomly select from data vectors in parent unit p]; 
(c) Calculate the Euclidean distances between v(t) and all units’ weight vectors w(t)p
h=1…V’ where V’ is the number of units in the newly generated map and p is discarded 
if this is the layer-0 map; 
(d) Determine the winner unit (BMU) of index u [Eq. 1]; 
(e) Compute the neighborhood function Lu(v),I [Eq.11]; 
(f) Update the weight vector of BMU unit and its neighbors [Eq. 2]; 
(g) Increment t and return to Step 3-b until tmax or map convergence is reached; 
4- Calculate the mean quantization error (mqei) of each object i in SOM[Eq. 3]; 
5- Calculate the SOM’s quantization error MQEm of map [Eq. 5]; 
6- If MQEm  T1 .m qeu where u is the parent unit of SOM map then 
(a) Find error unit (err) in map [Eq. 8]; 
(b) Find err's most dissimilar unit dist in map m [Eq. 9]; 
(c) Insert a new row or column between err and dist; 
(d) Initialize newly added units with the mean of their neighbors;  
(e) Return to Step 3-b; 
7- If any of SOM’s units (i) does not satisfy mqei < T2. mqe0  then 
(a) Expand the unit to form a new map at next hierarchical layer; 
(b) Return to Step 3-a; 
8- Return GHSOM a growing hierarchical map; 
 
Figure 4.4: GHSOM algorithm 
4.6.1 Input Data Vectors 
Data includes set of expression levels of genes that have been produced from tumor 
cells of breast cancer; we have different kind of datasets that are well described in 
chapter five. The microarray dataset is represented as a matrix of log (Intensity) 
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values, where the rows correspond to genes and the column correspond to samples. 
Each row represents one data vector for clustering. In the overall used datasets, there 
are (24,481) data vectors, each contains (117) samples. The attributes of this matrix 
are values of expression levels for genes related to breast cancer tissue; and thus the 
expression profiles of genes is up or down regulated.  
There are long biological methods to produce such data; this process is well 
described in chapter two. It starts by cDNA hybridization, then pass the resulted 
probes into microarray scanner to produce samples of expression levels. Definitely, 
the genes of interest described in chapter two are within the (24,481) vectors (rows) 
that we use in this thesis.  
 
4.6.2 Step2: Initialize Weight Vectors of Layer zero 
This step involved in initializing the weight vectors in random way for layer zero; the 
range of initialization varies between zero and the maximum number of microarray 
data vectors; i.e. maximum value is 24,481. 
 
4.6.3 Step3: Training a SOM 
For each layers of cluster in SOM (but not the layer zero), is initialized. The 
initialization values are produced as weighted average for each object’s parent and its 
neighborhood objects.  
At layer zero, a randomly v(t) from set {v1…v} is selected, where t is the training 
time. Whereas for lower layers, the v(t) is arbitrarily chosen from the set of parent 
objects. 
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Euclidean distance is calculated to find the distance between v(t) and the weight 
vectors of all the objects in the relevant SOM; the smallest distance of corresponding  
weight vector  identifies a cluster to which the microarray object v(t)  is probable to 
fit in. 
 
Next, GHSOM algorithm updates the weight vector of the best matching object u, as 
in the following neighborhood function L:   
 
L = (L0 * (-1 * (cc % EC*n) / PN )0.5 + 0.55               (11) 
Where n is the size of the input data, cc is current iteration, EC is the expand cycle 
parameter sets to 4; and initial neighborhood L0  is: 
 L0 =  (x or y / 2* (-1*log(NR))0.5 )0.5                (12) 
where NR represents the height of Gaussian Neighborhood, which is max X (width) 
or max Y (height) far from the winner; NR is parameter sets to 0.0006  
PN is stretch parameter neighborhood, it is calculated as: 
PN = (EC*n)/6.67                  (13) 
 
The winner vector is picked as follows: 
wi(t+1) = wi(t) + (t) [(v(t)-wi(t)]  for i=u and its neighbors             (14) 
where (t) is the neighborhood radius, which is the Gaussian kernel width; and it is 
calculated as: 
 = LR * (-1* (dist /2*L2) )0.5                           (15) 
LR is the initial learn rate, it determine how close the winner to its neighborhood, LR 
is a parameter sets to 0.5, this value is selected as the median between 0 and 1; dist is 
Euclidean distance calculated as follows: 
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dist = (vi[t] – vj[t]) * (vi[t] – vj[t])                             (16) 
Learning rate is chosen in such as way it decreases by time (t); this is for the quick 
convergence of maps. Thus, the winning vector moves slowly to the input space, the 
movement is controlled by the defined learning rate LR. The number of objects that 
are influenced is determined by neighborhood function, L; neighborhood function’s 
value is reduced by time.  
 
The idea in selecting the winner object and its neighbors yields to a spatial clustering 
of the Self Organizing Map.  
This training phase is iterative; it is repeated for a number of times for input data 
vectors. The stopping criterion is the convergence of the map.  
 
4.6.4 Step4 and Step5: Computing Quantization Error 
The quantization errors mqei [refer to equation (3)] for each object in the map are 
computed to indicate the closeness of this object to the data vector. Then, the mean 
of all mqei is calculated to show how good the representation of the data. 
 
4.6.5 Step6: Growing SOM 
After Step4 and Step5; GHSOM algorithm measures the quality of objects in the 
map (map) as the following: 
 If MQEmap  T1 .mqep , where p is the parent object of map, This means one or more 
objects are incorrectly clustered in a map; thus there is a need to enlarge the map 
size. T1 is a parameter value; we show in chapter five the best value for T1 is 0.04 in 
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our case. T1 controls the stopping criteria of the horizontal growth; i.e. the smaller 
T1 is the flatter the map will grow. 
 
4.6.6  Step7: Hierarchical Expansion 
GHSOM is characterized in hierarchical structure; thus the decision of hierarchal 
expansion (deeper layer) is controlled by calculating the quantization error. 
Therefore if mqei < T2. mqe0 is not satisfied, this means that the degree of level is not 
final. The smaller T2 , the bigger GHSOM structure; i.e deeper layers. T2 is a 
parameter value; we show in chapter five the best value for T2 is 0.003 in our case. 
 
4.6.7 Step8: Determining T1 
As explained in previous section, T1 controls the expansion of the map; i.e it controls 
how many clusters shall be added to a map and how many maps shall be added in 
same layer level. A map includes set of clusters of close microarray expression 
levels. T1 is the value used for horizontal stopping criterion; i.e. dissimilar 
microarray gene vectors are grouped in a wrong cluster; this results the need to add 
more clusters to allow more map expansion and hence better representation of the 
data. By setting T1 to a small value, we guarantee that genes of much similar 
expression levels will be within the same cluster. T1 is a parameter that range 
between 0 and 1. 
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4.6.8 Step9: Determining T2  
The second critical parameter is the T2, it controls the expansion of the layers. It 
controls the depth or the levels of GHSOM. T2 is the stopping criteria of a single 
level (layer), if the equation mqei < T2. mqe0 is not satisfied then more detailed layers 
further down are needed. T2 is a parameter that range between 0 and 1. 
 
In general, T1, T2 values are selected in a way that 1> T1 >> T2 > 0.  
 
4.6.9 Step10: Orientation parameter  
Third critical parameter is the orientation; it impacts the topology of resulted 
structure. Orientation addresses how weight vectors shall be computed in the lower 
layer based on their parent object. Random initialization is usually distorting the 
resulted topology; thus the orientation of each vector is based on their parent’s 
orientation. This attained by setting initial weight vectors in the newly produced 
SOM layer with values equivalent to their parent values. 
 
4.6.10 Clusters Validity 
The weight vectors in the map correspond to the projected data in a cluster. We 
interpret results of GHSOM by tracking the marker genes ESR1, BRCA1, BRCA2, 
IL1R1, and search the existence of genes of interest within the same clusters of the 
marker genes. We track the genes into lowest layers in GHSOM architecture. We 
select the sable genes of interest clustered with the four marker genes whatever the 
initial weight vectors, and regardless of selected neighborhood genes.  
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CHAPTER FIVE 
V-EXPERIMENTAL WORK 
5.1 Data Description  
We use DNA microarray of primary breast tumors of 117 young patients distributed 
over 4 Datasets [4]. The datasets are: 
 Dataset I: 34 samples x 24,481 genes from patients with distance metastases 
within period of five years; i.e, less than five years disease free survival.  
 Dataset II: 44 samples x 24,481 genes from patients who are cancer free 
after a period of five years or more; i.e., greater than five years disease free 
survival.  
 Dataset III: 20 samples x 24,481 genes from patients with BRCA2 carrier 
and BRCA1 germline mutations.  
 Dataset IV: 19 x 24,481 genes samples from additional patients profiled.   
All patients were young; i.e less than 55 years old at diagnosis. These patients were 
lymph node negative with tumor size less than 5 cm. Lymph node dissections is very 
known to define type of surgery in breast cancer; it also helps in developing the 
treatment plan. This analysis is done by removing part of the lymph nodes and send 
it to the pathology lab where they will carefully examined for cancer cells, if the 
lymph nodes test is negative; i.e, clear of cancer or positive; i.e contain cancer. This 
test is very crucial to define the staging of the breast cancer, to complete the 
diagnosis that influences the treatment options. However, some patients who have 
metastasis failed to show positive lymph node status; hence the test of lymph node 
and their historical grade was not sufficient to classify accurately breast tumor [4]. 
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Data includes 24481 genes “Name” and its “Description” – represented in 24481 
records. For each tumor sample profiled, there are three fundamental attributes given 
for each gene profiled: Log10(Intensity), Log10(ratio) and P-value. 
 Log10(Intensity) is the geometrical mean intensity for green and red spots for 
a probe on the chip.  In general, high quality data is derived from the genes 
associated with the greatest signal intensity. 
 Log10(ratio) is the mean ratio of the intensities of both green and red 
channels.  A mean ratio of 100 means that gene was induced 100 fold by the 
perturbation. A mean ratio of 0.01 means that gene was repressed 100 fold. 
 P-value is the confidence level of a gene’s mean ratio, it is significantly 
different from 1, or no change.  A P-value of 3.25E-03 = 0.00325, which 
exceeds the 99% confidence (P-value = -0.01, or 1E-02). 
In our experimental results, we apply GHSOM on the four datasets described above - 
(34) samples, (44) samples, (20) samples, (19) samples. In addition, we joined the 
four datasets to produce (117) samples (dataset V). 
 Dataset V: 117 samples x 24481 genes as a result of joining the previous four 
datasets I-IV into one large dataset. 
For each sample, we kept only the Log (Intensity) values for clustering, since it 
represents signal intensity of the position of the cDNA at each physical location. The 
signal intensity gives a measure of the number of bound molecules, which reflects 
the expression level of the gene. It also gives the identity of the molecules. Whereas 
the P-value and the Log(Ratio) indicate the level of accuracy and the quantitative 
measure of the relative gene expression level respectively [9]. Therefore, we produce 
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dataset VI by filtering the dataset V to have at least a twofold difference and a P-
value of less than 0.01 [4]: 
 Dataset VI: 8 samples x 24481 genes as a result of selecting expressions out 
of dataset V that are twofold difference and a P-value of less than 0.01. 
The microarray dataset is represented as a matrix of log (Intensity) values, where the 
rows correspond to genes and the column correspond to samples. Each row 
represents one data vector for clustering. In the overall datasets used, there are 
24,481 data vectors, each contains 117 samples. 
 
5.2 Experimental Procedure 
We apply GHSOM on six different datasets described in section 5.1; i.e.  Datasets: I, 
II, III, IV, V, and VI. 
GHSOM algorithm groups the genes - in each dataset - into clusters based on their 
expression level values. We aim to search for the 83 target genes described in section 
2.3 that tend to be clustered with the 4 marker genes described in section 2.3. In 
order to achieve this, we observe the genes that are clustered by applying GHSOM 
using various input parameter values T1 and T2. The selected range of values of T1 
and T2 is derived from previous publications [12], [15], [16], [17], [18]. Then we 
search for the best value of T2 by applying Quantum Clustering (QC) on the same 
datasets and compare the resulting number of clusters from QC with these of 
GHSOM. Note that we measure the reliability of QC clusters by applying Bayesian 
Information Criterion (BIC). In order to find the best value of T1 and further validate 
the value of T2, we calculate the quantization error of each cluster. The clusters 
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generated from GHSOM with minimum quantization error provide the best value of 
both T1 and T2.   
After we deduce the best value of T1 and T2 for GHSOM algorithm, we study the 
stability of our 83 genes of interest for that T1 and T2. We deduce a set of genes that 
always cluster with our marker genes; even while changing the range and the initial 
weight vectors in GHSOM and accordingly changing the selection set of 
neighborhood genes. Particularly, setting the Random Seeds variable to 17, 0, and 
2400, some of these Random Seeds values are deduced from previous publications 
[1], [15], [16], [17], [18], [20]. 
 
Finally, we compare GHSOM with SOM; i.e. the quantization error value of clusters 
using the breast cancer datasets; and then comparing the resulting genes with 
previous publications that applied SOM on breast cancer tissues. 
 
Summarizing our experimental procedures; we aim to address the following 
scenarios:  
 Scenario I: Apply GHSOM on the four different datasets I-IV for (T2  = 
0.003, T1 = 0.4), (T2 = 0.03, T1= 0.4), (T2 = 0.003, T1= 0.04), and (T2 = 0.03, 
T1= 0.04); T1 and T2 controls the breadth of maps and the depth of layers 
respectively; and then deduce from our genes of interest the ones that tend to 
be clustered with ESR1. 
 Scenario II: Apply GHSOM on the four different datasets datasets I-IV for 
(T2  = 0.003, T1 = 0.4), (T2 = 0.03, T1= 0.4), (T2 = 0.003, T1= 0.04), and (T2 = 
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0.03, T1= 0.04); and deduce from our genes of interest the ones that tend to be 
clustered with IL1R1. 
 Scenario III: Apply GHSOM on the four different datasets datasets I-IV for 
(T2  = 0.003, T1 = 0.4), (T2 = 0.03, T1= 0.4), (T2 = 0.003, T1= 0.04), and (T2 = 
0.03, T1= 0.04); and deduce from our genes of interest the ones that tend to be 
clustered with BRCA1. 
 Scenario IV: Apply GHSOM on the four different datasets datasets I-IV for 
(T2  = 0.003, T1 = 0.4), (T2 = 0.03, T1= 0.4), (T2 = 0.003, T1= 0.04), and (T2 = 
0.03, T1= 0.04); and deduce from our genes of interest the ones that tend to be 
clustered with BRCA2. 
 Scenario V: Select the best value T2 for GHSOM; we achieve this by 
applying another clustering algorithm (Quantum Clustering QC); validate QC 
clusters output by applying BIC; then compare the best result of QC clusters 
with GHSOM clusters.  
 Scenario VI: Select the best value of T1 for GHSOM, and validate the best 
value of T2 for GHSOM. We achieve this by calculating the cluster’s 
quantization error (QE) of the marker genes (ESR1, IL1R1, BRCA1, 
BRCA2) as a result of applying GHSOM on datasetsI-IV. Then we select the 
T1 and T2 that provides the minimum quantization error for all resulting 
clusters. However, Dittenbach & Rauber [15] used (T1 = 0.07 and T2 = 
0.0035) for GHSOM, therefore we add one more verification by applying 
GHSOM of these T1, T2 on one of the datasets; and we compare the resulting 
QE of clusters with our selected T1, T2.   
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So far we find the best values of T1 and T2 for GHSOM. Our next target in this 
research is to study the stability of our genes of interest within the resulting clusters; 
and deduce the best set of genes that tend to be clustered with the marker genes 
(ESR1, IL1R1, BRCA1, and BRCA2).  
 
 Scenario VII: Apply GHSOM using the selected T1 and T2 on the four 
different datasets I-IV. This time we set different initial vector weights and 
different neighborhood gene selection set; specifically set random seeds value 
equals to 0, 17, 24000 [1], [15], [16], [17], [18]; then deduce the stable genes 
of interest that tend to be clustered with ESR1.  
 Scenario VIII: Apply GHSOM of the selected T1 and T2 on the four different 
datasets I-IV, with different initial vector weights and different neighborhood 
gene selection set; specifically set random seeds value equals to 0,17,24000 
[1], [15], [16], [17], [18]; then deduce the stable genes of interest that tend to 
be clustered with IL1R1. 
 Scenario IX: Apply GHSOM of the selected T1 and T2 on the four different 
datasets I-IV., with different initial vector weights and different neighborhood 
gene selection set; specifically set random seeds value equals to 0,17,24000 
[1], [15], [16], [17], [18]; then deduce the stable genes of interest that tend to 
be clustered with BRCA1. 
 Scenario X: Apply GHSOM of the selected T1 and T2 on the four different 
datasets I-IV, with different initial vector weights and different neighborhood 
gene selection set; specifically for random seeds value equals to 0,17,24000 
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[1], [15], [16], [17], [18]; then deduce the stable genes of interest that tend to 
be clustered with BRCA2. 
 Scenario XI: Expand the analysis to apply GHSOM of selected T1 and T2 on 
dataset V, 117 samples, with different initial vector weights and different 
neighborhood genes selection set; specifically for random seeds value equals 
to 0,17,24000 [1], [15], [16], [17], [18]; then deduce the stable genes of 
interest that tend to be clustered with ESR1. 
 Scenario XII: Expand the analysis to apply GHSOM of selected T1 and T2 on 
dataset V, 117 samples, with different initial vector weights and different 
neighborhood gene selection set; specifically for random seeds value equals 
to 0,17,24000 [1], [15], [16], [17], [18]; then deduce the stable genes of 
interest that tend to be clustered with IL1R1. 
 Scenario XIII: Expand the analysis to apply GHSOM of selected T1 and T2 on 
dataset V, 117 samples, with different initial vector weights and different 
neighborhood genes selection set; specifically for random seeds value equals 
to 0,17,24000 [1], [15], [16], [17], [18]; then deduce the stable genes of 
interest that tend to be clustered with BRCA1. 
 Scenario XIV: Expand the analysis to apply GHSOM of selected T1 and T2 
on dataset V, 117 samples, with different initial vector weights and different 
neighborhood gene selection set; specifically for random seeds value equals 
to 0,17,24000; then deduce the stable genes of interest that tend to be 
clustered with BRCA2. 
 Scenario XV: Filter dataset V, (117) samples, so it has at least a twofold 
difference and a P-value of less than 0.01[4]. Veer [4] applied this filter on 
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the same breast cancer sample data we use in this research. Veer kept the 
gens that are significantly regulated across the group of samples. Referring to 
section 5.1 that describe Log10(ratio) and confidence level (P-value), we 
apply data filtering on the (117) samples keeping only the samples that 
satisfying both formulas Log10(ratio) >= 0.0002 and P-Value < 0.01. The 
result is Dataset VI. We apply GHSOM on dataset VI of selected T1 and T2. 
We produce the genes of interest that clustered with ESR1, IL1R1, BRCA1 
and BRCA2.  
 
5.3 Results and Observations for different: T1, T2 Scenarios I-IV 
We will depict and discuss the result of each scenario described in section 5.2. We 
have 15 scenarios that mapped into one or more experiments. 
We fix parameter T2 and change the value of T1: (T2 = 0.003, T1 = 0.4) & (T2 = 0.003, 
T1 = 0.04), to study the influence of map breadth on the architecture. Where T1 
controls the percentage of remaining errors in each map; i.e., it formulates the 
stopping criterion for horizontal growth in GHSOM.  As the value of T1 decreases, 
the map increases in size and the flatter the hierarchy of architecture will be. Table 
5.1 shows the different topological structure obtained with various values of T1. 
Varying the value of T2 helps to study the depth of the architecture; i.e. it helps in 
studying its impact on the vertical expansion (hierarchical). The smaller the value of 
T2, means more detailed layers will result, and thus the bigger the overall GHSOM 
hierarchical architecture. Results obtained are presented in Tables 5.1, this table 
shows the breadth changes: number of clusters in each map, the number of newly 
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obtained maps in each layer (level); and it shows the depth changes: the newly 
obtained layers (levels) while applying GHSOM on four different datasets of breast 
cancer, all datasets contain the same 24,481 genes. 
Table 5.1: Different topological structure obtained with various values of T1, T2 
 
GHSOM  
T1=0.4 
T2=0.03 
GHSOM  
T1=0.4 
T2=0.003 
GHSOM  
T1=0.04 
T2=0.03 
GHSOM  
T1=0.04 
T2=0.003 
Dataset I 
ArrayData_less_than_5yr 
 
(10)(2)(3)* (46)(4)(15) (11)(2)(2) (85)(3)(8) 
Dataset II 
ArrayData_greater_than_5y 
 
(10)(2)(3) (49)(4)(16) (28)(2)(3) (103)(3)(8) 
Dataset III 
ArrayData_BRCA1 
 
(10)(2)(3) (40)(4)(14) (11)(2)(2) (84)(3)(8) 
Dataset V 
ArrayData_19samples 
 
(10)(2)(3) (34)(4)(11) (11)(2)(2) (77)(3)(8) 
*Values in the table are: (total number of clusters) (total number of maps)(total number of layers/levels) 
 
 Results of Scenario I: We select the genes of interest mention in section 2.3; 
which occur more than 30% in the same cluster with ESR1 at the lowest layer out 
of the previous (16) experiments, we categorize these genes in a set A(ESR1), the 
resulting genes in the set A(ESR1) are: 
 
Figure 5.1: Genes clustered with ESR1 with 30% probability – set named as A(ESR1 
 Results of Scenario II: The genes of interest described in section 2.3; which occur 
more than 30% in the same cluster with IL1R1 at the lowest layer out of the 
previous (16) experiments, we categorize these genes in a set A(IL1R1), the 
resulting genes in the set A(IL1R1) are: 
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Figure 5.2: Genes clustered with IL1R1 with 30% probability – set named as A(IL1R1) 
 Results of Scenario III: The genes of interest described in section 2.3; which 
occur more than 30% in the same cluster with BRCA1 at the lowest layer out of 
the previous (16) experiments, we categorize these genes in a set A(BRCA1), the 
resulting genes in the set A(BRCA1) are: 
 
Figure 5.3: Genes clustered with BRCA1 with 30% probability – set named as A(BRCA1) 
Results of Scenario IV: The genes of interest described in section 2.3; which occur 
more than 30% in the same cluster with BRCA2 at the lowest layer out of the 
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previous (16) experiments, we categorize these genes in a set A(BRCA2), the 
resulting genes in the set A(BRCA2) are: 
 
Figure 5.4: Genes clustered with BRCA2 with 30% probability – set named as A(BRCA2) 
It is worth mentioning that a fixed set of genes always appear in the same cluster of 
(ESR1), (BRCA1), (BRCA2) and (IL1R1). This cluster results out from applying 
GHSOM on the same dataset. Since each dataset described in section 5.3 has its own 
characteristic, we deduce the following observations as a Result of Scenario I-IV:  
Table 5.2: Result of Scenario I-IV – Observations related to ESR1 gene 
Dataset Genes clustered with ESR1 Occurrence of these genes with  
ESR1 for different (T1,T2) combinations 
Dataset II: patients 
disease free > 5 years 
 
LIV-1, LAD1, RAC1 100% 
Dataset III: patients 
BRCA1 mutations & 
BRCA2 carrier 
 
IL1R1, ARHGEF1 100% 
GALNT3, PTENP1, 
PIK3R3, GEF, ARHGAP8 
75% 
Dataset V: Additional 
patients profiled 
 
LAD1 100% 
 
Table 5.3: Result of Scenario I-IV – Observations related to IL1R1 gene 
Dataset Genes clustered with IL1R1 Occurrence of these genes with  
IL1R1 for different (T1,T2) combinations 
Dataset I: disease free 
< 5 years 
 
CDC42 100% 
ARHGEF1 75% 
Dataset II: disease free 
> 5 years 
NAT1, ARHGEF1 75% 
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Dataset III: patients 
BRCA1 mutations & 
BRCA2 carrier 
 
PIK3R3, ARHGEF1 100% 
PTENP1 75% 
Dataset V: Additional 
patients profiled 
 
NAT1, ARHGEF1 100% 
 
Table 5.4: Result of Scenario I-IV – Observations related to BRCA1 gene 
Dataset Genes clustered with BRCA1 Occurrence of these genes with  
BRCA1 for different (T1,T2) combinations 
Dataset I: disease 
free < 5 years 
 
STAR, ARHGEF5, TIAM2, 
ARHGAP6, WASL, DIAPH1 
75% 
Dataset II: disease 
free > 5 years 
 
PIK3R3, PAK3, AKT2 100%
EGR4 75% 
Dataset III: patients 
BRCA1 mutations & 
BRCA2 carrier 
PAK1, T-STAR, EGF, EGFR, 
PLCD4, EGR4
100% 
TIAM2, VAV2, PLCG1, 
PAK2 
75% 
Dataset V: 
Additional profiled 
 
ARHGEF4, ARHGEF5 75% 
 
Table 5.5: Result of Scenario I-IV – Observations related to BRCA2 gene 
Dataset Genes clustered with BRCA2 Occurrence of these genes with  
BRCA2 for different (T1,T2) combinations 
Dataset I: disease 
free < 5 years 
 
T-STAR 100% 
STAR 75% 
Dataset III: patients 
BRCA1 mutations & 
BRCA2 carrier 
 
ARHGAP6, DIAPH1 100% 
ARHGEF5 75% 
Dataset V: 
Additional patients 
profiled 
 
PLCD4, EGR4 100% 
PAK2, PIK3C2A 75% 
 
Based on the results of scenario I-IV, we observe the following: 
1. CDH3, LIV-1, VAV3, LAD1, GATA3, GSTP1, SLPI, FABP7, RAB5EP, 
GALNT3, NAT1 genes are clustered with IL1R1 in the first layer; 
whereas NAT1 gene remains all the way with IL1R1 till its lowest layers. 
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2. It is noticed that IL1R1, ESRI are clustered together in the dataset of 
patients who are BRCA1 germline mutation and BRCA2 carrier. 
3. It is noticed that IL1R1, ESRI and BRCA1 are never clustered together. 
4. It is noticed that IL1R1, ESRI and BRCA2 are never clustered together. 
5. BRCA1 accompanies BRCA2 in its cluster until BRCA1 reaches its 
lowest layers; i.e, BRCA1 gene is always in same cluster of BRCA2, 
whereas BRCA2 splits sometimes away from BRCA1 to reach deeper 
layers. This shows a strong correlation between BRCA1 and BRCA2.  
6. ARHGEF1 accompanies IL1R1 in same cluster in most of the cases.  
7. IL1R1 is found on the border of its cluster; i.e, last gene order in its set.  
8. T-STAR, PAK, PIK3CD, ARHGEF5, PLCD4, EGR4, ARHGAP6, 
WASL, DIAPH1, EGFR are common genes that tend to be clustered with 
both BRCA1 and BRCA2. 
In the following section we will validate the selection of T1 and T2, and hence 
validate the results of clustered genes. 
 
5.4 Selection of T1 and T2: Scenarios V-VI  
We rely on some publications to determine the values of T1 and T2 [12], [15], [16], 
[17], [18]. These publications applied GHSOM on samples data for network 
intrusion detection, newsletters characterizing, and bookshelf creation applications. 
Hence the nature of these samples is different from microarray data that we adopt in 
this research. This leads to the need of validating the values of T1 and T2; which 
affects the produced clusters. 
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5.4.1 Determine an initial value for T2: Scenario V 
Quantum clustering (QC) algorithm depends on Schrodinger equation to provide a 
sufficient clustering of data. It requires one parameter  which is a Parzen window 
width.  controls the number of maps that will be produced. Increase the value of  
means producing less number of maps. Different  may also lead to the same number 
of maps but different assignment of objects within clusters. This algorithm is 
deterministic and thus we use it to verify GHSOM parameters. The algorithm is 
available online [23]. QC is used to cluster a microarray data such of Colon cancer 
data (2000 genes x 62 samples). The algorithm accepts two parameters: number of 
iteration and  range of values.  To compare our GHSOM results with the results of 
QC, we compare number of returned maps from GHSOM with the results of 
Quantum Clustering (QC) algorithm. 
QC needs two input parameters  and iteration; in order to mimic the constraints of 
GHSOM, we will set  to range from [0.003 to 0.4] and set iteration value to 50. 
According to Varshavsky [23] – for most practical cases – 50 iterations are found to 
be sufficient for running QC algorithm. By experiment, we find that setting the 
iteration value to 100,000 or 200,000 results the same number of clusters as setting 
the iteration to value 50. 
Varshavsky [23] applied Bayesian Information Criterion (BIC) to validate the 
reliability of clustering algorithm. BIC is defined as: 
BIC = -2*log(L)+f*log(|I|) 
Where L is the maximized value of the likelihood function for the estimated model, I 
is the sample size of the data, f is a function of the number of independent parameters 
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 Apply QC on Dataset II (patients who continued to be disease for a period 
greater than five years): the maximum value of BIC yields  = 0.3047 and 5 
clusters; refer to Figure 5.8. 
 Apply QC on Dataset III (patients with BRCA1 germline mutations and 
BRCA2 carrier): the maximum value of BIC yields  = 0.3762 and 5 clusters; 
refer to Figure 5.7. 
 Apply QC on Dataset IV (Additional patients profiled): the maximum value 
of BIC yields  equals to 0.3921 and 4 clusters; refer to Figure 5.6. 
 
Figure 5.6: Quantum clustering for Dataset IV,  = [0.003-0.4], and 50 iterations 
 
Figure 5.7: Quantum clustering for Dataset III,  = [0.003-0.4], and 50 iterations 
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Figure 5.8: Quantum clustering for Dataset II,  = [0.003-0.4], and 50 iterations 
 
Figure 5.9: Quantum clustering for Dataset I,  = [0.003-0.4], and 50 iterations 
The resulting clusters of the QC algorithm are compared to the resulting maps of the 
GHSOM algorithm. We found that for the best QC result, the value T2 equals to 
0.003 in GHSOM algorithm; refer to Figure 5.10.  
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        *(number of maps of GHSOM) 
** (number of clusters/maps of QC)(best  value based on highest BIC calculation) 
Figure 5.10: comparing Quantum clustering structure vs. GHSOM structure 
 
5.4.2 Determine the Value of T1 and T2: Scenario VI 
Validating the selection of T1 and T2 is important in our research. In previous 
section we applied QC-BIC and compared the resulting clusters with GHSOM, hence 
we determined an initial value for T2. 
In order to apply a second step validation for the value of T2 and find the best value 
for T1, we calculate the Quantization Error (QE) for all resulting clusters. QE is 
calculated for each resulting cluster in the lowest layer of the marker genes (ESR1), 
(BRCA1), (BRCA2), and (IL1R1). 
Comparing QE value for each; as a result of applying GHSOM on four T1 and T2 
combinations (T2  = 0.003, T1 = 0.4), (T2 = 0.03, T1= 0.4), (T2 = 0.003, T1= 0.04), and 
(T2 = 0.03, T1= 0.04) for Dataset IV. 
Table 5.6: Quantization error values by applying GHSOM on Dataset IV (Additional patients profiled) 
 
T1=0.4 
T2=0.03 
T1=0.4 
T2=0.003 
T1=0.04 
T2=0.03 
T1=0.04  
T2=0.003 
QE cluster of IL1R1 
 853.219 86.3633 1706.79 55.1938 
QE cluster of BRCA1 
 426.943 339.693 1149.21 33.7532 
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that is calculated by applying GHSOM on the same datasets for (T2= 0.0053, T= 
0.07). 
 
In section 5.5, we will address Scenario XV by applying data filter [4].  In section 
5.6, we will compare the values of Quantization Error resulted from GHSOM and 
SOM on same datasets, and discuss our contribution in enhancing the results.  Then 
in section 5.7, we will validate the resulting genes that tend to be clustered with the 
four marker genes by referring to biological references and previous publications 
about these genes; we will show from genetic description of the resulting genes their 
relationship to breast cancer and how they are involved in metastasis.  
 
5.5 Stability of GHSOM Clusters: Scenario VII-XV 
The value of Radom Seed in GHSOM algorithm stabilizes the range and the initial 
weight vectors values. Random sees enables repeatable training-runs. Changing the 
value of GHSOM Random Seed will set new range and new initial weights for  
vector data; hence it randomizes the selection set of neighborhood genes. 
 1- else if (strcmp(prop,"randomSeed")==0)   { 
 Globals::randomSeed = atol(val); 
 Globals::setRandom(Globals::randomSeed);} 
 
 2- void Globals::setRandom(unsigned int seed) {srand(seed);} 
 
 3- Neuron::Neuron(int ws,int ingid,int inlevel,int spx,int spy){ 
 weightsize = ws; 
 weights = (float *) calloc(weightsize,sizeof(float)); 
 for (int i=0;i<weightsize;i++) {weights[i] = Globals::getRandom();} 
 
 4- float Globals::getRandom() 
 {float res = (float)rand()/(float)RAND_MAX; 
 return res;} 
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In previous section we selected the best value of (T2= 0.003, T= 0.04); in this section, 
we will change the value of Random Seed RS = 0, RS = 17, RS = 24000 refer to 
Shah [1], Hayward [20], Dittenbach & Rauber [15]; then we study the stability of the 
genes of interest described in section 2.3. 
Table 5.11: Gene clusters with ESR1, IL1R1, BRCA1, BRCA2 with different seeds 
(a) Genes clustered with ESR1 in its lowest layer - GHSOM (T2= 0.003, T= 0.04) 
 Dataset I- less 
than 5 years 
disease free 
Dataset II- 
disease free 
after 5 years 
Dataset III- 
BRCA1/BRCA2 
mutations 
Dataset IV-
additional 
profiles 
 
Joined dataset 
(117 samples) 
RS=17 - (LIV-1) 
(LAD1) 
(RAC1) 
 
L2,M6,C1x6* 
(IL1R1) 
(PTENP1)  
(PIK3R3) 
(ARHGEF1) 
 
 
L2,M1,C3x1* 
(LAD1) 
(GSTP1) 
(RAC1) 
(GSTP1)
RS=0 (GSTP1) (LIV-1) 
(LAD1) 
(IL1R1) (LAD1) 
(GSTP1) 
(RAC1) 
 
(GSTP1)
RS=24000 (GSTP1) (LIV-1) 
(LAD1) 
(IL1R1)  (LAD1) 
(GSTP1) 
(LIV-1) 
 
(GSTP1)
(b) Genes clustered with IL1R1 in its lowest layer - GHSOM (T2= 0.003, T= 0.04) 
 Dataset I- less 
than 5 years 
disease free 
Dataset II- 
disease free 
after 5 years 
Dataset III- 
BRCA1/BRCA2 
mutations 
Dataset IV-
additional 
profiles 
 
Joined dataset 
(117 samples) 
RS=17 (ARHGDIB) 
(CDC42) 
(ARHGEF1) 
(ARHGEF16) 
(VEGF) 
(T-STAR) 
(NAT1) (PIK3R3)  
(ARHGEF1) 
(ESR1) 
 
L2,M4,C2x1* 
(ARHGEF1) 
(GEF) 
(ARHGAP8) 
RS=0 (NAT1) 
(GEF) 
(ARHGAP8) 
 
- (ESR1) (ARHGEF1) 
(PIK3R3) 
(GEF) 
(ARHGAP8) 
 
RS=24000 (GEF) 
(ARHGAP8) 
 
- (ESR1) - (GEF) 
(ARHGAP8) 
 
(c ) Genes clustered with BRCA1 in its lowest layer - GHSOM (T2= 0.003, T= 0.04) 
 
 Dataset I- less 
than 5 years 
disease free 
Dataset II- 
disease free 
after 5 years 
Dataset III- 
BRCA1/BRCA2 
mutations 
Dataset IV-
additional 
profiles 
Joined dataset 
(117 samples) 
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RS=17 (AKT3) 
(ARHGEF5) 
(TIAM2) 
(WASL) 
(DIAPH1) 
(WASPIP) 
(PIK3R3) 
(PAK3) 
(EGR4) 
(AKT2) 
(PIK3CB) 
(DIAPH2) 
(PAK1) 
(T-STAR) 
(ARHGAP6) 
(EGF) 
(EGFR) 
(PLCD4) 
(EGR4) 
(VAV1) 
 
L2,M6,C2x4* 
(ARHGEF4) 
(ARHGEF5) 
(BRCA2) 
(VAV1) 
RS=0 (PIK3CD) 
(TIAM2) 
(WASL) 
(DIAPH1) 
(PIK3R3) 
(PAK3) 
(EGR4) 
(AKT2) 
(EGFR) 
 
(BRCA2) 
(DIAPH1) 
(ARHGEF4) 
(ARHGEF5) 
 
(BRCA2) 
(ARHGEF5) 
(WASL) 
(ARHGEF9) 
(ARHGAP1) 
 
RS=24000 (PIK3CD) 
(ARHGEF5) 
 (WASL) 
 
(PIK3R3) 
(PAK3) 
(EGR4) 
(AKT2) 
 
(BRCA2) 
(DIAPH1) 
(ARHGEF4) 
(ARHGEF5) 
(BRCA2) 
(ARHGEF5) 
(WASL) 
(ARHGEF9) 
(ARHGAP1) 
 
(d) Genes clustered with BRCA2 in its lowest layer - GHSOM (T2= 0.003, T= 0.04) 
 
 Dataset I- less 
than 5 years 
disease free 
Dataset II- 
disease free 
after 5 years 
Dataset III- 
BRCA1/BRCA2 
mutations 
Dataset IV-
additional 
profiles 
 
Joined dataset 
(117 samples) 
RS=17 (STAR) 
(T-STAR) 
- (ARHGAP6) 
(DIAPH1) 
L2,M6,C2x1* 
(PLCD4) 
(EGR4) 
(PIK3C2A) 
 
(BRCA1) 
RS=0 - (TIAM2) 
(DIAPH1) 
(BRCA1) 
(DIAPH1) 
(PLCD4) 
(EGR4) 
(PIK3C2A) 
 
(BRCA1) 
 
RS=24000 (TIAM2) 
(DIAPH1) 
(DIAPH1) (BRCA1) 
(DIAPH1) 
(PLCD4) 
(EGR4) 
(PIK3C2A) 
 
(BRCA1) 
(DIAPH1) 
 
*L= layer number, M= Map number, C=cluster size (nxm) 
 Result of Scenario VII and Scenario XI: the stable genes that are clustered with 
ESR1 are:  
(GSTP1) gene appeared in many sample datasets; especially in the joined 
datasets (117) samples, Dataset I and Dataset IV. 
(LAD1) gene appeared in many sample datasets; especially in Dataset IV and 
Dataset II. 
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(IL1R1) gene appeared in all cases in Dataset III which contains samples of 
patients with BRCA1 mutations and BRCA2 carrier. 
(LIV1) gene appeared in Dataset II and once in Dataset IV. 
(RAC1) gene noticed to appear in some cases with same cluster with ESR1. If it 
is not in the same cluster, it remains in the same map layer with ESR1; i.e in 
ESR1 neighborhood. 
 
 Result of Scenario VIII and Scenario XII: the stable genes that are clustered with 
IL1R1 are: 
(GEF) gene appeared in many sample datasets; especially in the joined datasets 
(117) samples, Dataset I; similarly for (ARHGAP8) gene.  
(ESR1) gene is clustered, in all cases, in the Dataset III which contains samples 
of patients with BRCA1 mutations and BRCA2 carrier which contains samples of 
patients with BRCA1 mutations and BRCA2 carrier. 
(NAT1) gene appeared in many sample datasets; especially in Dataset II and 
Dataset I and Dataset IV. 
(ARHGEF1) gene appeared in many sample datasets; especially in Dataset III 
and Dataset I and Dataset IV. 
 
 Result of Scenario IX and Scenario XIII: the stable genes that are clustered with 
BRCA1 are:  
(ARHGEF4) and (ARHGEF5) genes appeared in all cases in Dataset IV; whereas 
(ARHGEF5) continue to appear in the joined dataset V and Dataset I. 
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(BRCA2) gene appeared in most of the cases; especially in the Joined dataset and 
Dataset III, which contains samples of patients with BRCA1 mutations and 
BRCA2 carrier. 
(WASL) genes appeared in all cases in Dataset I; it appeared in the joined dataset 
samples in the same cluster with BRCA1 or in its neighborhood cluster (both in 
the same map layer). 
(TIAM2) and (DIAPH1) genes appeared in all cases in Dataset I. Whereas 
(DIAPH2) appeared in Dataset II. 
(AKT2) genes appeared in all cases in Dataset II; whereas (AKT3) appeared in 
Dataset I. 
(PIK3R3) and (PAK3) genes appeared in all cases in Dataset II; whereas (PAK1) 
appeared in Dataset III. 
(EGR4) appeared in Dataset III; whereas (PIK3CB) appeared with BRCA1 in its 
neighborhood cluster (both in the same map layer). 
(VAV1) gene appeared in most cases with BRCA1 or in its neighborhood cluster 
(both in the same map layer) in dataset III and the joined dataset V. 
(ARHGAP6), (EGFR), (EGR4) and (PLCD4) genes appeared in most cases with 
BRCA1 or in its neighborhood cluster (both in the same map layer) in dataset III 
and the joined dataset V. 
 
 Result of Scenario X and Scenario XIV: the stable genes that clustered with 
BRCA2 are: 
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(BRCA1) gene appeared in most of the cases; especially in the Joined dataset and 
Dataset III, which contains samples of patients with BRCA1 mutations and 
BRCA2 carrier. 
(DIAPH1) appeared in Dataset III with BRCA1, or in its neighborhood cluster   
(both in the same map layer) in dataset II, and some cases in the joined dataset V 
and in dataset I. 
 (PLCD4), (EGR4), (PIK3C2A) appeared in Dataset IV in all cases. 
 
General Observation: 
(ARHGEF) family (ARHGEF1 & ARHGEF6) genes appeared in Dataset III which 
contains samples of patients with BRCA1 mutations and BRCA2 carrier with all 
marker genes (ESR1, BRCA1, BRCA2, and IL1R1) 
 
 Result of Scenario XV: We filter dataset V, (117) samples, so it has at least a 
twofold difference and a P-value of less than 0.01 [4]. The result is Dataset VI. 
We applied GHSOM on dataset VI of selected T1 and T2, and we produce the 
genes of interest that are clustered with ESR1, IL1R1, BRCA1 and BRCA2; the 
resulting genes are: 
(VAV3) appeared with ESR1 cluster. 
(AKT2), (PIK3R3), (PIK3R2) appeared with BRCA1 cluster. 
(EGR4) appeared with BRCA2 cluster. 
However, this filter needs further testing and analysis; we add it here in this 
research to open a new area for further research. 
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5.6 Comparison of GHSOM and SOM 
We compare each cluster’s quantization errors result from GHSOM with the ones 
result from SOM algorithm, both algorithms are applied on same datasets described 
in section 5.2. We apply SOM on each dataset by training SOM to a size 
approximately equals to the one resulte from GHSOM; i.e. equals to the total number 
of clusters in the lowest layer of ESR1, IL1R1, BRCA1 and BRCA2. We trained 
SOM for a total number of iteration equal to 5* data size. 
The values of cluster’s quantization error as a result of applying SOM (estimated 
cluster = 40) and GHSOM (T2= 0.003, T= 0.04) on Dataset I: patients less than five 
years disease free  
Table 5.12: comparing cluster quantization error by applying SOM and GHSOM on Dataset I 
  
SOM 
number of cluster = 5x8 
iteration = 5*24481 
 
GHSOM 
1=0.04  2=0.003 
 
% of enhancement 
QE cluster of IL1R1 
 294.584 644.21 119%
QE cluster BRCA1 
 912.893 172.2 81%
QE cluster BRCA2 
 879.214 288.393 67%
QE cluster ESR1 
 412.193 266.211 35%
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Figure 5.17: comparing clusters quantization error by applying SOM and GHSOM on Dataset I  
In this case, GHSOM outperforms SOM by enhancing the quantization error of 
ESR1 cluster by 35%, BRCA1 cluster by 81%, BRCA2 cluster by 67% and down 
perform IL1R1 by 119%. 
The values of cluster’s quantization error as a result of applying SOM (estimated 
clusters =56) and GHSOM (T2= 0.003, T= 0.04) on Dataset II: patients who 
continued to be disease for a period greater than five years 
Table 5.13: comparing cluster quantization error by applying SOM and GHSOM on Dataset II 
 SOM 
number of cluster = 7x8 
iteration = 5*24481  
GHSOM 
1=0.04  2=0.003 
% of enhancement  
QE cluster of IL1R1 
 453.003 205.529 55%
QE cluster BRCA1 
 838.057 413.914 51%
QE cluster BRCA2 
 1505.63 535.203 64%
QE cluster ESR1 
 410.103 609.203 49%
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Figure 5.18: comparing clusters quantization error by applying SOM and GHSOM on Dataset II 
In this example, GHSOM outperforms SOM by enhancing the quantization error of 
IL1R1 cluster by 55%, BRCA1 cluster by 51%, BRCA2 cluster by 64% and down 
perform ESR1 by 49%. 
 
The values of cluster’s quantization error as a result of applying SOM (estimated 
clusters = 54) and GHSOM (T2= 0.003, T= 0.04) on Dataset III: patients with 
BRCA1 germline mutations and BRCA2 carrier: 
Table 5.14: comparing cluster quantization error by applying SOM and GHSOM on Dataset III 
 SOM 
number of cluster = 6x9 
iteration = 5*24481  
GHSOM 
1=0.04  2=0.003 
% of enhancement  
QE cluster of IL1R1 
 130.379 92.8628 29%
QE cluster BRCA1 
 306.926 73.6731 76%
QE cluster BRCA2 
 222.529 151.134 32%
QE cluster ESR1 
 130.379 92.8628 29%
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Figure 5.19: comparing clusters quantization error by applying SOM and GHSOM on Dataset III 
We notice that GHSOM outperforms SOM by enhancing the quantization error of 
IL1R1 cluster by 29%, BRCA1 cluster by 76%, BRCA2 cluster by 32% and ESR1 
by 29%. 
 
The values of cluster’s quantization error as a result of applying SOM (estimated 
clusters = 42) and GHSOM (T2= 0.003, T= 0.04) on Dataset IV: Additional patients 
profiled: 
Table 5.15: comparing cluster quantization error by applying SOM and GHSOM on Dataset IV 
 SOM 
number of cluster = 7x6 
iteration = 5*24481  
GHSOM 
1=0.04  2=0.003 
% of enhancement  
QE cluster of IL1R1 
 83.1683 55.1938 34% 
QE cluster BRCA1 
 116.558 33.7532 71% 
QE cluster BRCA2 
 476.311 121.3 75% 
QE cluster ESR1 
 228.759 115.631 49% 
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Figure 5.20: clusters quantization error by applying SOM and GHSOM on Dataset IV 
It is clear that GHSOM outperforms SOM by enhancing the quantization error of 
IL1R1 cluster by 34%, BRCA1 cluster by 71%, BRCA2 cluster by 75% and ESR1 
by 49%. Hence, GHSOM outperforms SOM in terms of minimum clusters’ 
quantization error in 14 cases out of 16 ones. 
Moreover, it is worth mentioning that GHSOM performs faster than SOM as shown 
in table 5.16 due to GHSOM hierarchical nature while building its structure; i.e. 
GHSOM searches less number of vectors during iterations (selection set is reduced 
with time). 
Table 5.16: Performance of GHSOM v.s SOM on the four different datasets (in hours) 
Performance of GHSOM v.s SOM on the four different datasets (in hours) 
 
 Dataset I-  
less than 5 years 
disease free 
Dataset II- 
disease free 
after 5 years 
Dataset III- 
BRCA1/BRCA2 
mutations 
Dataset IV-
additional profiles 
 
GSHOM 
 17.9 27.1 8.9 8.4 
SOM 
 32.3 38.8 36.7 47.7 
% of 
enhancement 44.58% 30.15% 75.75% 82.39% 
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5.7 Analysis and Interpretation of GHSOM Results 
We are first who applied GHSOM clustering to microarray data, to the best of our 
knowledge, and first who tracked the genes throughout various experiments. 
However, modeling gene expression data is very challenging with respect to the huge 
number of genes involved and the high level of noise. Generally speaking, there are 
two main methodologies: supervised learning and unsupervised learning [10]. Many 
classification and clustering techniques show promising results in several gene-
expression cancer diagnostic experiments [10]. Moreover, classification of gene-
expression is involved in reducing high feature dimension and identifies subset of 
gene markers [10]; this amplifies our choice of clustering to mine microarray genes 
based on their expression levels.  
 
With reference to bio-genetic description of genes and their possible relation to 
breast cancer and metastasis, and with reference to previous publications; we 
conclude the following interesting outcomes: 
 
Correlation between (GSTP1), (LAD1), (IL1R1), (LIV1) genes with ESR1 and with 
breast cancer:  
GSTP1 is usually up regulated in human cancers since it plays important role in 
detoxification; therefore it’s over expressed as tumor developed, and it results in 
resistance to treatments [6]. This strengthens our observation of the close relationship 
between GSTP1 and ESR1. Our results show that GSTP1 and ESRI remain in the 
same clusters in almost all of the datasets/experiments. LAD1 which is ladinin 1, it is 
clustered with ESR1 in many samples in this thesis; Gruzdz [6] applied SOM on 
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breast cancer microarray dataset, he showed that LAD1 is negatively correlated with 
ESR1. Covell [8] applied SOM on breast cancer datasets; he concluded that IL1R1 
gene shows differential gene expression by being up-regulated in breast tumor cells 
and down-regulated in normal cells. IL1R1 gene (interleukin 1 receptor-like 1) which 
is thought to be part of the regulation mechanisms in protumorigenic activities; the 
involvement of IL1R1 in such activities may be related to breast cancer of human 
[8]. We showed that IL1R1 tends to be clustered with ESR1 in samples of patients 
with BRCA1 mutations and BRCA2 carrier. (LIV1) is LIV-1 protein, estrogen 
regulated, is a breast cancer associated protein relevant to tumor development 
because it is responsible for the zinc transportation [6]; which supports our 
observation of the close relationship between LIV1 and ESR1, especially for the 
samples of patients who continue to be disease free after (5) years of receiving 
treatments. 
 
Correlation between (GEF), (ESR1), (ARHGAP8) genes with IL1R1 and with breast 
cancer:  
ARHGAP gene (synonym to RhoGAP, p50rhoGAP, CDC42GAP, Cdc42GAP) and 
ARHGEF: Rho GTPases are known to be involved in the stimulation of cell cycle 
progression. The family of Rho GTPases contains 20 small G proteins playing 
important roles in the regulation of the cytoskeleton, the cell cycle, the cell migration 
and the cell polarity. ARHGEF4 and ARHGEF5 both are observed to be clustered 
with BRCA1. Referring to their genome summary, Rho GTPases plays an essential 
role in cellular mechanisms through G protein coupled receptors. Splicing of 
(ARHGEF4) produces two transcript variants which encode different isoforms; 
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ARHGEF5 protein may be involved in the control of organization of cytoskeletal 
(NCBI RefSeq 2008). ARHGEF1 and ARHGEF6: genes are of Rho GTPases family, 
involved in significant cellular mechanisms (NCBI RefSeq, Jul 2008). Rho GTPases 
are guanine nucleotide binding proteins existing in two forms: the active form which 
is GTP bound and the inactive one that being GDP bound and it is important to note 
that only in the active form, Rho GTPases can interact with other effectors mediating 
their cellular functions. Rho GTPases are regulated by GAPs (GTPase activating 
proteins) and GEFs (guanine nucleotide exchange factors). GEF activates Rho 
GTPases by exchanging GDP for GTP while GAP inhibits these proteins by 
hydrolyzing GTP to GDP. Since Rho GTPases are positive regulators of cell cycle 
progression, mutations in Rho GTPases and their regulators are expected to lead to 
tumor formation. Indeed many mutations in Rho GTPases have been correlated with 
many types of cancers, including breast cancer. In this thesis, we find the level of 
expression of two regulators of Rho GTPases to be altered in breast cancer. GEF 
gene is found to be regulated with IL1R1 in this research. The official name of GEF 
is ARHGEF2, its functions Rho GTPases play a significant role in cellular 
mechanisms that are triggered by extracellular stimuli through receptor tyrosine 
kinases leading to cell metastasis and proliferation (NCBI RefSeq 2009). ARHGAP8 
gene encodes a member of the RHOGAP family. GAP (GTPase-activating) family 
proteins contribute in regulate cell processes responsible on cytoskeletal changes 
(NCBI RefSeq 2010). ESR1 is estrogen receptor 1; this gene encodes an estrogen 
receptor, responsible for hormone and DNA binding, and transcription’s activation. 
“Estrogen receptors are involved in pathological processes including breast cancer, 
endometrial cancer, and osteoporosis” (NCBI RefSeq 2008). We found a strong 
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correlation between ESRI and IL1R1 in the dataset of which contains samples of 
patients with BRCA1 mutations and BRCA2 carrier. 
ARHGEF1 and ARHGEF6: of Rho GTPases family, involved in significant cellular 
mechanisms (NCBI RefSeq, Jul 2008). 
 
Correlation between (ARHGEF4), (ARHGEF5), (BRCA2), (WASL), (AKT2), 
(PIK3R3), (PAK3), (EGR4) genes with BRCA1 and with breast cancer:  
ARHGEF4 and ARHGEF5 both are observed to be clustered with BRCA1. Referring 
to their genome summary: Rho GTPases plays an essential role in cellular 
mechanisms through G protein coupled receptors. Splicing of ARHGEF4 produces 
two transcript variants which encode different isoforms; ARHGEF5 protein may be 
involved in the control in organization of cytoskeletal (NCBI RefSeq 2008). BRCA2 
gene appeared in most of the cases; especially in the joined dataset V and Dataset III, 
which contains samples of patients with BRCA1 mutations and BRCA2 carrier. 
Inherited BRCA2 mutations increases lifetime risk of developing ovarian or breast 
tumors. Both BRCA1 and BRCA2 are significant in genome stability; specifically, 
the homologous recombination pathway for double-strand DNA repairs. BRCA2 is 
considered a tumor suppressor gene (NCBI RefSeq, 2008). WASL: is a gene 
clustered with BRCA1 in Dataset I, it contains samples from patients who are less 
than five years disease free; this gene also clustered with BRCA1 or in its 
neighborhood in the dataset that contains the whole 117 breast cancer samples joined 
in one dataset. WSAL (Wiskott-Aldrich syndrome) family of proteins associates with 
the small GTPase directly or not; it shows highest expression in neural tissues (NCBI 
RefSeq, 2008). WASP: is a nucleation promoting factor that is activated downstream 
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of Rho GTPases and activate nucleation factors, such as Diaphenous proteins and 
Arp2/3, leading to actin polymerization and cell motility. AKT2 was discovered to 
be over-expressed in many ovarian carcinoma subtype and ovarian tumors. AKT2 
alternation involved in malignant phenotype pancreatic cancers (NCBI RefSeq, 
2008). PIK3R3 belongs to family of lipid kinases; which is responsible for 
organizing cellular functions such as cell survival. Activating mutations in the 
p110alpha- recently discovered in certain kinds of cancer cells (TOCRIS-website). 
PAK: leads to actin polymerization needed for cell motility. PAK3 gene is PAK 
proteins link Rho GTPases to cytoskeleton reorganization and nuclear signaling. 
PAK protein is involved in many biological activities. Defects in PAK3 are the cause 
of non-syndromic mental retardation (NCBI RefSeq, 2008). EGR4 is the early 
growth response 4.  
 
Correlation between (BRCA1), (DIAPH1), (PLCD4), (EGR4), (PIK3C2A) with 
BRCA2 and with breast cancer:  
BRCA1 gene appeared in most of the cases; especially in the joined dataset V and 
Dataset III, which contains samples of patients with BRCA1 mutations and BRCA2 
carrier. This gene is important in genomic stability, and it also acts as a tumor 
suppressor. Mutations in BRCA1 is known to be the cause of more than forty percent 
of inherited breast tumors, and more than eighty percent of inherited ovarian and 
breast tumors (NCBI RefSeq, 2009). Diaph: Diaphenous is an actin nucleator leading 
to actin polymerization and cell motility. DIAPH1 gene is significant in actin 
polymerization regulation in hair cells of the inner ear and encoding various isoforms 
(NCBI RefSeq, 2008). PLC delta: is activated downstream from receptor tyrosine 
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kinases which respond to growth factors and it is associated with increased cell 
motility and proliferation through its effect on actin and PKC, respectively. PLCD4 
gene encodes C enzymes, which plays a significant role in cellular processes; also 
expression alternation of PLCD4 is possible cancer marker (NCBI RefSeq, 2011). 
EGR4 is the early growth response 4. 
PI3K: A lipid kinase that leads to the phosphorylation of phosphoinositides on the 
third hydroxyl position. One of the main products of PI3K is PIP3. Many proteins 
have a PH domain that binds to PIP3. Hence these proteins are recruited by PI3K 
near to their regulators and downstream effectors. Included in the list of these 
proteins, activated downstream from PI3K, are the serine threonine kinase Akt and 
Rho GEFs. Through these pathways PI3K leads to the activation of survival and the 
cell cycle, hence the PI3K pathway is oncogenic and its deregulation correlated with 
tumor formation. PIK3C2A gene: the protein encoded by this gene belongs to PI3K 
family. This family plays important role in signaling pathways contributes in cell 
transformation, migration and survival (NCBI RefSeq, Jul 2008). Akt is a serine 
threonine kinase that phosphorylates downstream targets leading to increased 
proliferation and decreased apoptosis. AKT2 gene was discovered to be over-
expressed in many ovarian carcinoma subtype and ovarian tumors. AKT2 alternation 
involved in malignant phenotype pancreatic cancers (NCBI RefSeq, 2008). PIK3R3 
gene belongs to family of lipid kinases; which is responsible for organizing cellular 
functions such as cell survival. Activating mutations in the p110alpha- recently 
discovered in certain kinds of cancer cells (TOCRIS-website). BRCA2 and BRCA1: 
is clustered in most of the datasets in our thesis work; especially in the dataset that 
contains the whole 117 breast cancer samples joined in one dataset V, and in Dataset 
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III which contains samples of patients with BRCA1 mutations and BRCA2 carrier; 
inherited BRCA2 mutations increases lifetime risk of developing ovarian or breast 
tumors. Both BRCA1 and BRCA2 are significant in genome stability; specifically, 
the homologous recombination pathway for double-strand DNA repairs. BRCA2 is 
considered a tumor suppressor gene (NCBI RefSeq, 2008). BRCA1: gene is 
important in genomic stability, and it also acts as a tumor suppressor. Mutations in 
BRCA1 is known to be the cause of more than forty percent of inherited breast 
tumors, and more than eighty percent of inherited ovarian and breast tumors (NCBI 
RefSeq, 2009). In addition, EGR4 gene is known as the early growth response 4. 
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CHAPTER SIX 
VI-Conclusion and Further Work 
6.1 Conclusion 
We designed GHSOM for unsupervised clustering of  breast cancer datasets of 
microarray genes. We applied GHSOM to cluster 24,481 genes of DNA microarray 
for 117 patients. Based on the genes alternations and their expression levels, we 
clustered the genes of interest and tracked the four marker genes (ESR1, IL1R1, 
BRCA1, and BRCA2). We analyzed and interpreted these genes in different 
scenarios, and we found a set of stable genes that tend to be clustered with ESR1, 
and they are: LIV-1, LAD1, IL1R1, and GSTP1. The stable genes that are correlated 
with IL1R1 are:  ESR1, GEF, ARHGAP8; and stable genes that tend to be clustered 
with BRCA1 are: WASL, AKT2, EGR4, PAK3, PIK3R3, ARHGEF5, ARHGEF4, 
BRCA2. Also we found stable genes that are clustered with BRCA2, and they are: 
DIAPH1, PIK3C2A, EGR4, PLCD4 and BRCA1. Refer to table 6.1 for more details 
about the clustered genes per each datasets. 
Table 6.1: results of genes clustered with the four marker genes (ESR1, IL1R1, BRCA1, BRCA2) 
Genes clustered with ESR1 in its lowest layer - GHSOM (T2= 0.003, T= 0.04) 
 Dataset I- less 
than 5 years 
disease free 
Dataset II- 
disease free 
after 5 years 
Dataset III- 
BRCA1/BRCA2 
mutations 
Dataset IV-
additional 
profiles 
 
Joined dataset 
(117 samples) 
 - (LIV-1) 
(LAD1)  
 
(IL1R1) 
 
 
(LAD1) 
(GSTP1) 
(GSTP1)
Genes clustered with IL1R1 in its lowest layer - GHSOM (T2= 0.003, T= 0.04) 
 Dataset I- less 
than 5 years 
disease free 
Dataset II- 
disease free 
after 5 years 
Dataset III- 
BRCA1/BRCA2 
mutations 
Dataset IV-
additional 
profiles 
 
Joined dataset 
(117 samples) 
 - - (ESR1)
 
- (GEF) 
(ARHGAP8) 
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Genes clustered with BRCA1 in its lowest layer - GHSOM (T2= 0.003, T= 0.04) 
 
 Dataset I- less 
than 5 years 
disease free 
Dataset II- 
disease free 
after 5 years 
Dataset III- 
BRCA1/BRCA2 
mutations 
Dataset IV-
additional 
profiles 
 
Joined dataset 
(117 samples) 
 (WASL) 
 
(PIK3R3) 
(PAK3) 
(EGR4) 
(AKT2) 
 
- (ARHGEF4) 
(ARHGEF5) 
(BRCA2) 
 
Genes clustered with BRCA2 in its lowest layer - GHSOM (T2= 0.003, T= 0.04) 
 
 Dataset I- less 
than 5 years 
disease free 
Dataset II- 
disease free 
after 5 years 
Dataset III- 
BRCA1/BRCA2 
mutations 
Dataset IV-
additional 
profiles 
 
Joined dataset 
(117 samples) 
 - -  (DIAPH1) (PLCD4) 
(EGR4) 
(PIK3C2A) 
 
(BRCA1) 
 
Summarizing the genes that contribute to cell metastasis, it is known that Rho 
GTPases is involved in stimulation cell cycle progression. Rho GTPases is 
nucleotide binding by GTP (active form) and GDP (inactive form). GAP regulates 
Rho GTPases by hydrolyzing GTP to GDP (active to inactive form); whereas EGF 
activates Rho GTPases by exchanging GDP for GTP (inactive to active form). 
Among the genes of interest we analyzed and monitored: ARHGEF1, ARHGEF6, 
ARHGEF4 and ARHGEF5 that are of Rho GTPases family. In addition, ARHGAP8 
encodes a member of the RHOGAP family.  
IL1R1 is up-regulated in breast cancer tumor and down regulated in normal breast 
cancer tumor, it is quite interesting to notice that GEF is clustered with IL1R1. The 
protein encoded by PIK3C2A gene belongs to PI3K. PI3K is responsible for tumor 
formation and organizing cell functions, PI3K down streams GEF.  
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Mutations in Rho GTPases and their regulators are expected to lead to tumor 
formation. In addition, Rho GTPases activates downstream WASP that is responsible 
on actin polymerization and cell motility; both WASP and DIAPH1 are actin 
polymerization associated with BRCA2 in the samples of BRCA mutations that we 
analyzed, and they both lead to cell motility. Rho GTPases related directly or 
indirectly to WASL that is clustered with BRCA1 in the samples with less than 5 
years diseases free. PAK3 holds protein that is linked to Rho GTPases and it is 
responsible also for polymerization and cell motility. 
PLCD4 alternation is possible cancer marker and it is clustered with BRCA2. AKT2 
is over expressed in ovarian and pancreatic carcinoma; we found that AKT2 is 
correlated to BRCA1 in the samples of disease free after 5 years of therapy; similarly 
for EGR4.  
 
Figure 6.1: Resulting genes and their relationship to metastasis and marker genes 
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GSTP1, LAD1, and LIV1 are correlated to ESR1 negatively or positively. 
In addition, we find that BRCA1 and BRCA2 are always correlated in the 117 
samples. ESR1 and IL1R1 are always correlated in samples with BRCA mutations. 
The result described in table 6.1 provides biologists with a limited set of genes that 
are likely to be correlated with breast cancer marker genes, and they are involved 
with metastasis. Our result is promising since it revealed 17 genes for biologists to 
verify and monitor the results in the wet labs. This result can be exploited to improve 
breast cancer diagnosis and its therapy development. 
 
6.2 Further Work 
Grouping genes microarray of breast cancer into classes that can be categorized 
based on similarity of their expression profiles. This can be done by associating 
genes with clinical outcomes and environmental factors, which is considered as 
future research objective.  
We would like to expand this research by validating the relationship between 
clustered genes with ESR1, IL1R1, BRCA1 and BRCA2 as a result of this thesis by 
using biological verification. Validating our results in the laboratory will certainly 
bring valid and concrete proof on the reported genes and their relationship to breast 
cancer tumors; which may be involved in monitoring treatment responses for 
different states of human breast cancer. In addition, involving healthy tissues and 
compare it with tumors tissues by both computational analysis and biological 
verification will certainly bring outstanding results. 
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Another idea for future research, is to test the output of GHSOM choosing different 
neighborhood function while applying clustering, in this research we used only 
Gaussian Neighborhood at map border. 
Moreover, we would like to work more on the input data by applying preprocessing 
methods on data before clustering it. This would help in extracting noise from the 
input data, and to work with more confident gene expression values. We hope we can 
apply this kind of data filtering with the help of a biologist.  
In addition, we hope to study the effectiveness of different distance functions applied 
on GHSOM, such as Spearman ranked correlation, Kendall’s tau, city-block 
distance, and many others; note that we applied Euclidian distance in this thesis. 
Another future objective we aim to is to validate the resulting clusters by applying 
Bayesian Information Criteria (BIC) on GHSOM to determine best input parameters. 
Moreover, we hope in the future to mix different samples of human breast cancers 
tissues like samples from MIT, Norway/Stanford, PNAS; then to apply data mining 
techniques such as clustering and classification to produce partitioning criteria for 
samples based on their clinical features. For instance, produce set of association rules 
from genes that have similar expression profiles and grouped them by patients’ age, 
ERP status, tumor stage, BRCA mutations, and months of survival. Moreover, we 
can use different types of tumor mixed together, such as ovarian, pancreatic and 
breast tumors. Then we can apply data mining techniques to result sets of separating 
genes between these tumor types. 
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Appendices 
Appendix I 
Gene Name Gene Description 
ESR1  estrogen receptor 1 
BRCA1  breast cancer 1, early onset 
BRCA2 breast cancer 2, early onset 
IL1R1  interleukin 1 receptor, type I 
CDH3 cadherin 3, type 1, P-cadherin (placental) 
LIV-1 LIV-1 protein, estrogen regulated 
VAV3 vav 3 oncogene 
 LAD1 ladinin 1 
 GATA3  GATA-binding protein 3 
GSTP1 glutathione S-transferase pi 
SLPI secretory leukocyte protease inhibitor (antileukoproteinase) 
FABP7 fatty acid binding protein 7, brain 
RAB5EP rabaptin-5 
GALNT3 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 3 (GalNAc-T3) 
 
NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase) 
RAC1  ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding 
protein Rac1) 
 
PIK3R2 phosphoinositide-3-kinase, regulatory subunit, polypeptide 2 (p85 beta) 
 
ARHGEF16 putative neuroblastoma protein 
VASP vasodilator-stimulated phosphoprotein 
VAV3 vav 3 oncogene 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 
DIA1 diaphorase (NADH) (cytochrome b-5 reductase) 
EGFL3 EGF-like-domain, multiple 3 
EGR1 early growth response 1 
T-STAR Sam68-like phosphotyrosine protein, T-STAR 
DJ-1 RNA-binding protein regulatory subunit 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 
RAC3 ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding 
protein Rac3) 
 
RHO6 GTP-binding protein 
RHO7 GTP-binding protein Rho7 
RHO rhodopsin (opsin 2, rod pigment) (retinitis pigmentosa 4, autosomal 
dominant) 
 
CDC42 cell division cycle 42 (GTP-binding protein, 25kD) 
ROCK2 Rho-associated, coiled-coil containing protein kinase 2 
LIMK1 LIM domain kinase 1 
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AKT1 v-akt murine thymoma viral oncogene homolog 1 
AKT2 v-akt murine thymoma viral oncogene homolog 2 
AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, 
gamma) 
 
PTENP1 phosphatase and tensin homolog (mutated in multiple advanced cancers 1), 
pseudogene 1 
 
PIK3C2B phosphoinositide-3-kinase, class 2, beta polypeptide 
PIK3C2A  phosphoinositide-3-kinase, class 2, alpha polypeptide 
PIK3CA  phosphoinositide-3-kinase, catalytic, alpha polypeptide 
PIK3CB phosphoinositide-3-kinase, catalytic, beta polypeptide 
PIK3CD phosphoinositide-3-kinase, catalytic, delta polypeptide 
PIK3CG phosphoinositide-3-kinase, catalytic, gamma polypeptide 
PIK3C3 phosphoinositide-3-kinase, class 3 
PIK3R3 phosphoinositide-3-kinase, regulatory subunit, polypeptide 3 (p55, gamma) 
 
GEF ESTs 
ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1 
ARHGEF2 rho/rac guanine nucleotide exchange factor (GEF) 2 
ARHGEF4 Rho guanine nucleotide exchange factor (GEF) 4 
ARHGEF5 Rho guanine nucleotide exchange factor (GEF) 5 
ARHGEF6 Rac/Cdc42 guanine exchange factor (GEF) 6
ARHGEF9 Cdc42 guanine exchange factor (GEF) 9 
STAR steroidogenic acute regulatory protein 
TRIO triple functional domain (PTPRF interacting) 
EGR4 early growth response 4 
EGFR epidermal growth factor receptor (avian erythroblastic leukemia viral  
(v-erb-b) oncogene homolog) 
 
EGFL6 EGF-like-domain, multiple 6 
EGFL5 EGF-like-domain, multiple 5 
EGF epidermal growth factor (beta-urogastrone) 
PLCD4 ESTs, Weakly similar to  
PLCD1 phospholipase C, delta 1 
PLCG2 phospholipase C, gamma 2 (phosphatidylinositol-specific) 
PLCG1 phospholipase C, gamma 1 (formerly subtype 148) 
PLCB4 phospholipase C, beta 4 
DIAPH3 Homo sapiens mRNA; cDNA DKFZp434C0931 (from clone 
DKFZp434C0931); partial cds 
DIAPH2 diaphanous (Drosophila, homolog) 2 
DIAPH1 diaphanous (Drosophila, homolog) 1 
WASPIP Wiskott-Aldrich syndrome protein interacting protein 
WASL Wiskott-Aldrich syndrome-like 
IQGAP2 IQ motif containing GTPase activating protein 2 
ARHGAP8 Rho GTPase activating protein 8 
ARHGAP6 Rho GTPase activating protein 6 
ARHGAP1 Rho GTPase activating protein 1 
VAV2 vav 2 oncogene 
VAV1 vav 1 oncogene 
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SMURF1 E3 ubiquitin ligase SMURF1 
VEGFB vascular endothelial growth factor B 
VEGF vascular endothelial growth factor 
TIAM2 T-cell lymphoma invasion and metastasis 2 
PAK6 p21-activated protein kinase 6
PAK3 p21 (CDKN1A)-activated kinase 3 
PAK2 p21 (CDKN1A)-activated kinase 2 
PAK1 p21/Cdc42/Rac1-activated kinase 1 (yeast Ste20-related) 
CDC42BPB CDC42-binding protein kinase beta (DMPK-like) 
ARHGEF12 Rho guanine exchange factor (GEF) 12 
ARHGEF11 Rho guanine exchange factor (GEF) 11 
ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 10 
 
 
